UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 10-Q

 


 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarter ended June 30, 2024

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                             to                          

 

Commission File Number 000-53601

 

MITESCO, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada

87-0496850

(State Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification Number)

 

505 Beachland Blvd., Suite 1377

Vero Beach, Florida 32963

(Address of principal executive offices) (Zip code)

 

844-383-8689

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

 

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large, accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer

Smaller reporting company

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No

 

As of August 14, 2024, the registrant had 6,358,582 shares of common stock issued and outstanding.

 

 

 

 

Table of Contents

 

 

Page

PART I  FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements (Unaudited)

4

 

Consolidated Balance Sheets as of June 30, 2024, and December 31, 2023

4

 

Consolidated Statements of Operations for the three and six months ended June 30, 2024, and 2023

5

 

Consolidated Stockholder’s Deficit for the three and six months ended June 30, 2024, and 2023

6

 

Consolidated Statements of Cash Flows for the six months ended June 30, 2024, and 2023

7

 

Notes to Consolidated Financial Statements

8

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

28

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

32

 

 

 

Item 4.

Controls and Procedures.

32

 

 

 

PART II  OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings.

33

 

 

 

Item 1A.

Risk Factors.

34

 

 

 

Item 2.

Sale of Unregistered Securities.

35

 

 

 

Item 3.

Defaults Upon Senior Secured Securities.

35

 

 

 

Item 4.

Mine Safety Disclosures.

35

 

 

 

Item 5.

Other Information.

35

 

 

 

Item 6.

Exhibits.

35

 

 

 

Signatures

37

 

 

 

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

MITESCO, INC.

CONSOLIDATED BALANCE SHEETS

 

   

June 30, 2024

(Unaudited)

   

December 31, 2023

 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 40,196     $ 2,838  

Prepaids and other current assets

    6,000       -  

Total current assets

    46,196       2,838  
                 

Total assets

  $ 46,196     $ 2,838  
                 

LIABILITIES AND STOCKHOLDERS' DEFICIT

               

Current liabilities:

               

Accounts payable and accrued liabilities

  $ 7,350,307     $ 7,838,112  

Accrued interest

    449,455       348,821  

Accrued interest - related party

    82,845       61,792  

Derivative liabilities

    152,945       152,945  

Lease liability - operating lease, current

    99,477       99,477  

Notes payable, net

    1,244,429       945,429  

Notes payable - related parties, net

    300,012       300,012  

SBA loan payable

    408,303       421,788  

Other current liabilities

    96,136       121,136  

Preferred stock dividends payable

    2,338,790       1,551,833  

Preferred stock dividends payable - related parties

    209,364       73,364  

Legal settlements

    2,452,768       2,219,886  

Total current liabilities

    15,184,831       14,134,595  
                 

Total liabilities

    15,184,831       14,134,595  
                 

Stockholders' deficit

               

Preferred stock, $0.01 par value, 100,000,000 shares authorized; 500,000 shares designated Series A; 3,000,000 shares designated Series C; 10,000,000 shares designated Series D; 10,000 shares designated as Series E; 140,000 shares designated as Series F, and 27,324 shares designated Series X.

               

Preferred stock, Series A, $0.01 par value, 0 shares issued and outstanding as of June 30, 2024, and December 31, 2023

    -       -  

Preferred stock, Series C, $0.01 par value, 0 shares issued and outstanding as of June 30, 2024, and December 31, 2023

    -       -  

Preferred stock, Series D, $0.01 par value, 250,000 shares issued and outstanding as of June 30, 2024, and December 31, 2023

    2,500       2,500  

Preferred stock, Series F, $0.01 par value, 20,057 shares issued and outstanding as of June 30, 2024, and December 31, 2023

    201       201  

Preferred stock, Series X, $0.01 par value, 31,427 and 24,227 shares issued and outstanding at June 30, 2024, and December 31, 2023

    314       242  

Common stock, $0.01 par value, 500,000,000 shares authorized, 5,958,582 and 5,567,957 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

    59,587       55,680  

Additional paid-in capital

    47,211,508       47,856,444  

Accumulated deficit

    (62,412,745 )     (62,046,824 )
                 

Total stockholders' deficit

    (15,138,635 )     (14,131,757 )
                 

Total liabilities and stockholders' deficit

  $ 46,196     $ 2,838  

 

See accompanying notes to these unaudited consolidated financial statements.

 

 

MITESCO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

Three Months Ended

   

Six Months Ended

 
   

June 30, 2024

   

June 30, 2023

   

June 30, 2024

   

June 30, 2023

 
                                 

Revenue

  $ 6,000     $ -     $ 6,000     $ -  
                                 

OPERATING EXPENSES:

                               
                                 

General and administrative

    345,877       558,277       481,353       2,188,180  

Impairment of fixed assets

    -       3,535       -       132,000  
                                 

Total operating expenses

    345,877       561,812       481,353       2,320,180  
                                 

Net loss from operations

    (339,877 )     (561,812 )     (475,353 )     (2,320,180 )
                                 

OTHER INCOME (EXPENSES):

                               

Interest expense

    (67,603 )     (129,436 )     (108,227 )     (1,505,502 )

Interest expense - related parties

    (4,965 )     (29,954 )     (15,546 )     (73,523 )

Equity investment incentive

    -       (6,429,107 )     -       (6,429,107 )

Gain on termination of operating lease

    -       -       233,205       -  

Gain on forgiveness of debt

    -       25,000       -       25,000  

Gain on sale of assets

    -       20,097       -       20,097  

Gain on issuance of shares to service provided

    -       33,092       -       33,092  

Loss on settlement of true-up obligations

    -       (119,370 )     -       (119,370 )

Loss on legal settlement

    -       (18,759 )     -       (18,759 )

(Loss) Gain on revaluation of derivative liabilities

    -       39,738       -       (71,040 )

Total other income (expense)

    (72,568 )     (6,608,699 )     109,432       (8,139,112 )
                                 

Net loss from continuing operations

    (412,445 )     (7,170,511 )     (365,921 )     (10,459,292 )

Net loss from discontinued operations

    -       (373,759 )     -       (2,698,803 )

Consolidated net loss

    (412,445 )     (7,544,270 )     (365,921 )     (13,158,095 )
                                 

Preferred stock dividends

    (309,143 )     (409,420 )     (859,455 )     (471,243 )

Preferred stock dividends - related parties

    (47,747 )     (59,125 )     (136,000 )     (77,121 )
                                 

Net loss available to common shareholders

  $ (769,335 )   $ (8,012,815 )     (1,361,376 )     (13,706,459 )
                                 

Net loss per common share - continuing operations

  $ (0.15 )   $ (1.50 )     (0.25 )     (2.23 )

Net loss per common share - discontinued operations

  $ (0.00 )   $ (0.06 )     (0.00 )     (0.53 )

Net loss per common share

  $ (0.15 )   $ (1.55 )     (0.25 )     (2.76 )
                                 

Weighted average shares outstanding

    5,802,968     $ 5,157,610       5,698,479       4,963,755  

 

See accompanying notes to these unaudited consolidated financial statements.

 

 

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSDEFICIT

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024, and 2023

(UNAUDITED)

 

   

Preferred Stock

Series C

   

Preferred Stock

Series D

   

Preferred Stock

Series F

   

Preferred Stock

Series X

   

Common Stock

   

Additional

Paid-in

   

Common

Stock

   

Accumulated

         
   

Shares

 

Amount

   

Shares

 

Amount

   

Shares

 

Amount

   

Shares

 

Amount

   

Shares

 

Amount

   

Capital

   

Subscribed

   

Deficit

   

Total

 
                                                                                                       

Balance, December 31, 2023

    -   $ -       250,000   $ 2,500       20,057   $ 201       24,227   $ 242       5,567,957   $ 55,680     $ 47,856,444     $ -     $ (62,046,824 )   $ (14,131,757 )
                                                                                                       

Shares issued for Series X dividends

    -     -       -     -       -     -       -     -       66,070     661       52,195       -       -       52,856  

Preferred stock dividends

    -     -       -     -       -     -       -     -       -     -       (638,565 )     -       -       (638,565 )

Net income

    -     -       -     -       -     -       -     -       -     -       -       -       46,524       46,524  
                                                                                                       

Balance, March 31, 2024

    -     -       250,000     2,500       20,057     201       24,227     242       5,634,027     56,341       47,270,074       -       (62,000,300 )     (14,670,942 )
                                                                                                       

Shares issued for Series X dividends

    -     -       -     -       -     -       -     -       24,555     246       19,396       -       -       19,642  

Shares issued as compensation

    -     -       -     -       -     -       -     -       300,000     3,000       99,000       -       -       102,000  

Preferred stock dividends

    -     -       -     -       -     -       -     -       -     -       (356,890 )     -       -       (356,890 )

Series X shares issued as compensation

    -     -       -     -       -     -       7,200     72       -     -       179,928       -       -       179,928  

Net loss

    -     -       -     -       -     -       -     -       -     -       -       -       (412,445 )     (412,445 )
                                                                                                       

Balance, June 30, 2024

    -   $ -       250,000   $ 2,500       20,057   $ 201       31,427   $ 314       5,958,582   $ 59,587     $ 47,211,508     $ -     $ (62,412,745 )   $ (15,138,635 )
                                                                                                       
                                                                                                       

Balance, December 31, 2022

    1,047,619     10,476       3,100,000     31,000       -     -       24,227     242       4,630,372     46,305       29,452,514       36,575       (48,714,461 )     (19,137,349 )
                                                                                                       

Shares issued for conversion of note payable

    -     -       -     -       -     -       -     -       57,138     571       82,885       -       -       83,456  

Vesting of stock options issued to employees

    -     -       -     -       -     -       -     -       -     -       933       -       -       933  

Shares issued to service providers

    -     -       -     -       -     -       -     -       300,000     3,000       894,000       -       -       897,000  

Shares issued for Series X dividends

    -     -       -     -       -     -       -     -       8,063     81       35,248       -       -       35,329  

Preferred stock dividends

    -     -       -     -       -     -       -     -                     (79,818 )     -       -       (79,818 )

Net loss

    -     -       -     -       -     -       -     -       -     -       -       -       (5,613,825 )     (5,613,825 )
                                                                                                       

Balance, March 31, 2023

    1,047,619     10,476       3,100,000     31,000       -     -       24,227     242       4,995,573     49,957       30,385,762       36,575       (54,328,286 )     (23,814,274 )
                                                                                                       

Shares issued as commission for fundraising

    -     -       -     -       -     -       -     -       2,952     30       3,778       -       -       3,808  

Shares issued for true-up agreement

    -     -       -     -       -     -       -     -       94,738     947       118,423       -       -       119,370  

Shares issued legal settlement

    -     -       -     -       -     -       -     -       22,174     222       18,537       -       -       18,759  

Shares issued for previously subscribed shares

    -     -       -     -       -     -       -     -       2,926     30       36,545       (36,575 )     -       -  

Shares issued for Series X dividends

    -     -       -     -       -     -       -     -       20,212     202       25,033       -       -       25,235  

Vesting of stock options issued to employees

    -     -       -     -       -     -       -     -       -     -       933       -       -       933  

Series F shares issued for conversion of accounts payable

    -     -       -     -       147     2       -     -       -     -       146,212       -       -       146,214  

Series F shares sold for cash

    -     -       -     -       1,746     17       -     -       -     -       1,655,483       -       -       1,655,500  

Series F shares issued for conversion of Series C and Series D preferred shares

    (1,047,619 )   (10,476 )     (2,350,000 )   (23,500 )     6,344     63       -     -       -     -       2,809,415       -       -       2,775,502  

Series F shares issued for conversion of debt

    -     -       -     -       8,116     81       -     -       -     -       8,612,993       -       -       8,613,074  
Series A dividends previously satisfied     -     -       -     -       -     -       -     -       -     -       10,967       -       -       10,967  

Preferred stock dividends

    -     -       -     -       -     -       -     -       -     -       (468,545 )     -       -       (457,578 )

Net loss

    -     -       -     -       -     -       -     -       -     -       -       -       (7,544,270 )     (7,544,270 )
                                                                                                       

Balance, June 30, 2023

    -   $ -       750,000   $ 7,500       16,353   $ 163       24,227   $ 242       5,138,575   $ 51,388     $ 43,355,536     $ -     $ (61,872,556 )   $ (23,814,274  

 

See accompanying notes to these unaudited consolidated financial statements.

 

MITESCO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   

Six Months Ended

 
   

June 30, 2024

   

June 30, 2023

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               

Net income loss from continuing operations

  $ (365,921 )   $ (10,459,292 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Impairment of right of use asset

    -       132,000  

Depreciation expense

    -       11,393  

Penalties on notes payable

    -       1,102,778  

Equity investment incentive

            6,501,107  

Amortization of discount on notes payable

    -       32,011  

Amortization of discount on notes payable - related parties

    -       19,617  

Share based compensation

    282,000       898,866  

Shares issued as compensation for fundraising

    -       3,808  

Shares issued for true-up liability

    -       119,370  

Gain on forgiveness of note payable

    -       25,000  

Gain (loss) on lease terminations

    (233,205 )     -  

Gain (loss) on revaluation of derivative liabilities

    -       71,040  

Loss on legal settlement

    -       18,759  

Changes in operating assets and liabilities:

               

Accounts receivable

    (6,000 )     -  

Prepaid expenses

    -       51,632  

Accounts payable and accrued liabilities

    (46,718 )     757,397  

Other current liabilities

            25,000  

Accrued interest

    100,634       257,650  

Accrued interest - related parties

    21,053       57,796  

Net cash used in operating activities from continuing operations

    (248,157 )     (424,068 )

Net cash provided by operating activities from discontinued operations

    -       (94,164 )

Net cash used in operating activities

    (248,157 )     (518,232 )
                 
                 

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Principal payments on SBA Loan

    (13,485 )     -  

Proceeds from notes payable, net of discounts

    299,000       -  

Proceeds from sale of Series F Preferred stock, net of fees

    -       738,500  

Net cash provided by financing activities from continuing operations

    285,515       738,500  

Net cash provided by financing activities from discontinued operations

    -       -  

Net cash provided by financing activities

    285,515       738,500  
                 

Net change in cash

    37,358       220,268  

Cash at beginning of period

    2,838       35,623  

Cash at end of period

  $ 40,196     $ 255,891  
                 

Supplemental disclosure of cash flow information:

               

Cash paid for interest

  $ -     $ -  

Cash paid for taxes

  $ -     $ -  
                 

Supplemental disclosure of financing cash flow information:

               

Stock Issued for common stock subscribed

  $ -     $ 82,885  

Preferred stock dividends

  $ 995,455     $ 548,363  

Conversion of accounts payable to Series F preferred stock

  $ -     $ 146,214  

Conversion of Series C and Series D preferred stock to Series F preferred stock

  $ -     $ 420,681  

Conversion of notes payable and accrued interest to Series F preferred stock

  $ -     $ 8,111,253  

Shares issued for Series X dividends

  $ 72,498     $ 60,564  

Increase in capital expenditures included in accounts payable

  $ -     $ 110,511  

 

See accompanying notes to these unaudited consolidated financial statements.

 

 

MITESCO, INC.

UNAUDITED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1: Description of Business

 

Company Overview

 

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company completed a move of its corporate status to Nevada from Delaware in order to effect reduced costs.

 

The details can be found at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518523001074/mitesco20231016_8k.htm .

 

From 2020 through 2022, our operations were focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability.

 

We are a holding company seeking to provide products, services and technology. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS).

 

In June 2024 we announced the formation of two (2) new wholly owned business units, Centcore, LLC, who is providing data center services including cloud computing and application hosting, and Vero Technology Ventures, LLC, whose aim is to seek investment and acquisition opportunities, generally in the areas of cloud computing and data center related applications.

 

Centcore has two (2) areas of focus. The first, generic data center services, is aimed at hosting applications for a specific user, sometimes referred to as “managed services offerings” or MSO, where the client moves the software licensed from various vendors, or internally developed, into our data center where we maintain the computing, communications and backup environment. The second focus involves hosting application software developed by software vendors, from which they will sell the use of the software by their end user clients on a “cloud” basis. By taking this approach we gain the business of the vendor, and their clients, perhaps allowing us to grow at a faster rate with lower cost of sales. We have developed the “Centcore Partner Program” where we will help promote the software vendors who are hosting in our data centers. If we are successful helping the vendor grow his business, we will have provided a “value added service”, and benefit from increased utilization of our computing resources by not only the vendor, but also his new end user clients. Our initial focus for this area is on software providers who serve the “infrastructure” market doing design, engineering, construction and maintenance of significant assets. We desire to create “life cycle” relationships with both the design teams, and owners which may include private owners such as manufacturers and utilities, or publicly owned assets for municipalities, states or federal governments, domestically and internationally.

 

We have retained proven professionals in the data center, cyber security and infrastructure services areas to support our needs on a per hour basis, which we believe will allow us to control our costs relative to business activity, without significant staffing internally.

 

Note 2: Going Concern

 

As of June 30, 2024, the Company had cash and cash equivalents of approximately $40,000, current liabilities of approximately $15.2 million, and has incurred significant losses from the previous clinic operations. As previously noted, we made a strategic decision to reduce our capital needs by closing our entire clinic operations in the fourth quarter of 2022 and releasing our entire staff, due to lack of profitability. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

 

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

 

 

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

 

Note 3: Summary of Significant Accounting Policies

 

Basis of Presentation – The consolidated financial statements are prepared in conformity with accounting principles accepted in the United States of America (“GAAP”).

 

The consolidated financial statements and related disclosures as of June 30, 2024, are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. In our opinion, these unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited financial statements should be read in conjunction with the audited financial statements of the Company for the years ended December 31, 2023, and 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024. The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year ended December 31, 2024.

 

Principles of Consolidation The accompanying consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC, The Good Clinic, LLC, Vero Technology Ventures, LLC, and Centcore, LLC. In addition, we relied on the operating activities of certain legal entities in which we did not maintain a controlling ownership interest, but over which we had indirect influence and of which we were considered the primary beneficiary. These entities are typically subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

 

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options, and convertible instruments. For the three and six months ended June 30, 2024, the effect of 673,208 warrants to purchase shares of common stock, 13,667 options to purchase shares of common stock, and 1,216,616 shares of common stock issuable upon conversion of Series D preferred stock were excluded from the calculation of net loss per share as their effect was antidilutive. For the three and six months ended June 30, 2023 the effect of 673,208 warrants to purchase shares of common stock, 209,381 options to purchase shares of common stock, and 3,467,464 shares of common stock issuable upon conversion of Series D preferred stock were excluded from the calculation of net loss per share as their effect was antidilutive.

 

Discontinued Operations - The accompanying financial statements are prepared with the guidance of ASU 2014-08, “Reporting Discontinued Operations”, and ASC Topic 205, Presentation of Financial Statements, and ASC Topic 360, Property, Plant and Equipment.

 

Recent Accounting Standards – In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

 

There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

 

 

Note 4: Discontinued Operations

 

In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability. On December 8, 2023, the Company sold the remaining assets of The Good Clinic, LLC to Leading Primary Care LLC, a company organized by Michael C. Howe, the former CEO of The Good Clinic, LLC for total consideration of approximately $2.5 million. ASC 360-10-45-9 requires that a long-lived asset (disposal group) to be sold shall be classified as held for sale in the period in which a set of criteria have been met, including criteria that the sale of the asset (disposal group) is probable and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. This criterion was achieved on December 8, 2023. Additionally, the discontinued operations are comprised of the entirety of The Good Clinic, LLC. For comparability purposes certain prior period line items relating to the assets held for sale have been reclassified and presented as discontinued operations for all periods presented in the accompanying consolidated statements of net loss and comprehensive loss and the consolidated balance sheets.

 

The Company had no assets or liabilities classified that were classified as held as part of discontinued operations as of June 30, 2024, or December 31, 2023.

 

The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations:

 

   

Three Months Ended

   

Six Months Ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Revenue

  $ -     $ -     $ -     $ -  

Cost of goods sold

    -       5,601       -       8,020  

Gross margin

            (5,601 )     -       (8,020 )
                                 

Selling, general, and administrative expenses

    -       (216,404 )     -       (597,905 )

Impairment of assets

    -       (68,034 )     -       (2,211,462 )
                                 

Other (income) expense:

                               

Gain on termination of operating lease

    -       -       -       287,897  

Interest expense

    -       (83,720 )     -       (169,313 )

Loss from discontinued operations, net of tax

  $ -     $ (373,759 )   $ -     $ (2,698,803 )

 

The following information presents the major classes of line items constituting significant operating and investing cash flow activities in the consolidated statements of cash flows relating to discontinued operations:

 

   

Six Months Ended

 
   

June 30,

   

June 30,

 
   

2024

   

2023

 
                 

Depreciation expense

  $ -     $ 81,764  

Impairment of property and equipment

  $ -     $ 2,211,462  

Changes in accounts payable and accrued liabilities

  $ -     $ 444,884  

 

Note 5: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at June 30, 2024, and December 31, 2023:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Trade accounts payable

  $ 6,516,812     $ 7,094,334  

Accrued payroll and payroll taxes

    833,495       743,778  

Total accounts payable and accrued liabilities

  $ 7,350,307     $ 7,838,112  

 

 

Note 6: Right to Use Assets and Lease Liabilities Operating Leases

 

The Company had operating leases for its clinics for which the Company is currently in negotiations with the Lessors to settle the remaining amounts owed after closing the clinic facilities. The Company’s lease expense was entirely comprised of operating leases and is reported as a component of discontinued operations as a result of closing of the clinics and the subsequent sale of the assets. As of December 31, 2023, the Company had impaired all balances of the related right to use assets.

 

Operating lease liabilities are summarized below:

 

   

June 30 30,

2024

   

December 31,

2023

 

Lease liability

  $ 99,477     $ 99,477  

Less: current portion

    (99,477 )     (99,477 )

Lease liability, non-current

  $ -     $ -  

 

As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2023, or the six months ending June 30, 2024. As of June 30, 2024, the Company has either settled amounts owed or entered into default judgements for all leases except for the office lease, which we believe is nominal. For all leases for which a legal settlement has been entered into, all amounts have been reclassified to legal settlements as of June 30, 2024, and December 31, 2023.

 

For the period ended December 31, 2024

  $ 99,477  

For the period ended December 31, 2025

    -  

For the period ended December 31, 2026

    -  

For the period ended December 31, 2027

    -  

For the period ended December 31, 2028

    -  

Thereafter

    -  

Total

  $ 99,477  

Less: Present value discount

    -  

Lease liability

  $ 99,477  

 

As of December 31, 2023, the Company has entered into settlement agreements for certain of our leases in the amount of $2,219,886 which is recorded as Legal Settlements in the accompanying balance sheet. During the six months ended June 30, 2024, the Company recorded a gain of $233,205 as a result of a final settlement in addition to reclassifying certain accounts payable related to the leases to legal settlements. As of June 30, 2024, the Company has total legal settlement agreements in the amount of $2,452,768 which is recorded as Legal Settlements in the accompanying balance sheet.

 

Note 7: SBA Loan Payable

 

PPP Loan Conversion to SBA Loan

 

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration (the “SBA”). On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year.

 

On July 12, 2023, the Company received confirmation of a payment plan arrangement from the SBA. Pursuant to this payment plan, the Company agreed to pay a minimum of $2,595 each month until the loan is paid in full in July 2028. The SBA confirmed the balance due on the loan, including principal and interest, was $467,117. The Company will amortize the balance due on the loan including interest at the original PPP loan rate of 1% per annum; a gain on restructure of debt in the amount of $40,622 was recorded on this transaction during the year ended December 31, 2023, and the balance of the loan was recorded at the amount of $433,343 representing the net cash flows discounted at 1%. During the six months ended June 30, 2024, the Company made principal payments of $13,485 on this loan and recorded interest in the amount of $2,087.

 

 

Note 8: Notes Payable

 

The following table summarizes the outstanding notes payable as of June 30, 2024, and December 31, 2023, respectively:

 

   

June 30, 2024

   

December 31, 2023

 

Kishon Note

  $ 431,666     $ 431,666  

Finnegan Note 1

    51,765       51,765  

Finnegan Note 2

    32,353       32,353  

Schrier Note

    25,882       25,882  

Nommsen Note

    64,705       64,705  

Caplan Note

    64,705       64,705  

Finnegan Note 3

    32,353       32,353  

Lightmas Note

    66,000       66,000  

Lewis Note

    33,000       33,000  

Goff Note

    33,000       33,000  

Hagan Note

    110,000       110,000  

Cavalry Note 1

    25,000       -  

Cavalry Note 2

    50,000       -  

Mercer Note 1

    25,000       -  

Mercer Note 2

    50,000       -  

ABJ Note

    50,000       -  

Cavalry Note 3

    33,000       -  

Mercer Note 3

    33,000       -  

ABJ Note 2

    33,000       -  

Notes Payable

    1,244,429       945,429  
                 

Current Portion

    1,244,429       945,429  

Long-term portion

  $ -     $ -  

 

Kishon Note

 

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

 

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022, and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492.

 

During the year ended December 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note. At December 31, 2023, principal and interest in the amount of $431,666 and $88,909, respectively, were due on the Kishon Note. At June 30, 2024, principal and interest in the amount of $431,666 and $127,653, respectively, were due on the Kishon Note. This note was in default at June 30, 2024.

 

 

Finnegan Note 1

 

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1.

 

Principal and accrued interest in the amount of $51,765 and $11,889, respectively, were due on this note at December 31, 2023. At June 30, 2024, principal and interest in the amount of $51,765 and $16,142, respectively, were due on the Kishon Note. This note was in default at June 30, 2024.

 

Finnegan Note 2

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2.

 

At December 31, 2023principal and accrued interest in the amount of $32,353 and $7,341, respectively, were due on this note. At June 30, 2024, principal and interest in the amount of $32,353 and $9,999, respectively, were due on the Kishon Note. This note was in default at June 30, 2024.

 

Schrier Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note.

 

At December 31, 2023, principal and accrued interest in the amount of $25,882 and $5,383, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $25,882 and $7,510, respectively, were due on this note. This note was in default at June 30, 2024.

 

 

Nommsen Note

 

On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $13,685, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $64,705 and $19,001, respectively, were due on this note. This note was in default at June 30, 2024.

 

Caplan Note

 

On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $12,989, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $64,705 and $18,305, respectively, were due on this note This note was in default at June 30, 2024.

 

Finnegan Note 3

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3.

 

At December 31, 2023, principal and accrued interest in the amount of $32,353 and $6,350, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $32,353 and $9,008, respectively, were due on this note. This note was in default at June 30, 2024.

 

 

Lightmas Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the “Lightmas Note”). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note.

 

At December 31, 2023, principal and accrued interest in the amount of $66,000 and $13,325, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $66,000 and $18,748, respectively, were due on this note. This note was in default at June 30, 2024.

 

Lewis Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the “Lewis Note”). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note.

 

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $33,000 and $9,374, respectively, were due on this note. This note was in default at June 30, 2024.

 

Goff Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the “Goff Note”). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note.

 

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $33,000 and $9,374, respectively, were due on this note. This note was in default at June 30, 2024.

 

 

Hagan Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the “Hagan Note”). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note.

 

At December 31, 2023, principal and accrued interest in the amount of $110,000 and $21,793, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $110,000 and $30,831, respectively, were due on this note. This note was in default at June 30, 2024.

 

Cavalry 2024 Note 1

 

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Cavalry Fund LLP (“Cavalry”), (the “Cavalry Note 1”) with a due date of January 23, 2025. The Cavalry Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $25,000 and $1,587, respectively, were due on this note.

 

Cavalry 2024 Note 2

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Cavalry, (the “Cavalry Note 2”) with a due date of February 28, 2025. The Cavalry Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $2,688, respectively, were due on this note.

 

Cavalry 2024 Note 3

 

On May 13, 2024, the Company issued a 10% Promissory Note in the principal amount of $33,000 to Cavalry, (the “Cavalry Note 3”) with a due date of May 13, 2025. The Cavalry Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $434, respectively, were due on this note.

 

Mercer 2024 Note 1

 

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Mercer Street Global Opportunity Fund (“Mercer”), (the “Mercer Note 1”) with a due date of January 23, 2025. The Mercer Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $25,000 and $1,587, respectively, were due on this note.

 

 

Mercer 2024 Note 2

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mercer, (the “Mercer Note 2”) with a due date of February 28, 2025. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $2,675, respectively, were due on this note.

 

Mercer 2024 Note 3

 

On May 13, 2024, the Company issued a 10% Promissory Note in the principal amount of $33,000 to Mercer, (the “Mercer Note 3”) with a due date of May 13, 2025. The Mercer Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $416, respectively, were due on this note.

 

AJB 2024 Note 1

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB Capital Investments, LLC (“AJB”), (the “AJB Note 1”) with a due date of February 28, 2025. The AJB Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $2,605, respectively, were due on this note.

 

AJB 2024 Note 2

 

On May 15, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB, (the “AJB Note 2”) with a due date of May 15, 2025. The AJB Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $416, respectively, were due on this note.

 

Aggregate interest expense on the above notes payable was $108,227 for the six months ended June 30, 2024. Accrued interest on notes payable was $449,455 and $348,821 at June 30, 2024, and December 31, 2023, respectively.

 

Note 9: Notes Payable Related Parties

 

The following table summarizes the outstanding related party notes payable as of June 30, 2024, and December 31, 2023, respectively.

 

   

June 30,

2024

   

December 31,

2023

 

M Diamond Note

    64,706       64,706  

Dobbertin Note

    19,412       19,412  

Lindstrom Note

    45,294       45,294  

Mitchell Note

    78,100       78,100  

Leath Note

    55,000       55,000  

November 29, 2022, Notes

    37,500       37,500  

Notes Payable

    300,012       300,012  
                 

Current Portion, net of discount

  $ 300,012     $ 300,012  

Long-term portion, net of discount

    -       -  

 

 

M Diamond Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). Ms. Diamond is the daughter of Larry Diamond, former CEO. The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,706 and $14,682, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $64,706 and $17,636, respectively, were due on this note. This note was in default at June 30, 2024.

 

Dobbertin Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, who was the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note.

 

At December 31, 2023, principal and accrued interest in the amount of $19,412 and $4,405, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $19,412 and $5,989, respectively, were due on this note. This note was in default at June 30, 2024.

 

Lindstrom Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, who was the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1.

 

At December 31, 2023, principal and accrued interest in the amount of $45,294 and $10,277, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $45,294 and $13,973, respectively, were due on this note. This note was in default at June 30, 2024.

 

 

Mitchell Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note.

 

At December 31, 2023, principal and accrued interest in the amount of $78,100 and $15,768, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $78,100 and $22,185, respectively, were due on this note. This note was in default at June 30, 2024.

 

Leath Note

 

On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the “Leath Note”). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $50,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note.

 

At December 31, 2023, principal and accrued interest in the amount of $55,000 and $10,757, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $55,000 and $15,276, respectively, were due on this note. This note was in default at June 30, 2024.

 

November 29, 2022, Notes

 

On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, who was the Company’s CFO and Board Member; (2) Lawrence Diamond, who was the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, who was a Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, who was a Board Member; (6) Jenny Lindstrom, who was the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, who was the Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”).

 

The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 13. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022, because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022.

 

 

Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022.

 

During the year ended December 31, 2023, interest in the amount of $11,967 was accrued on the November 29 Notes.

 

On September 29, 2023, three of the November 29 Lenders (1) Thomas Brodmerkel, (2) Lawrence Diamond, and (3) Faraz Naqvi converted their November 29 Notes into shares of the Company’s Series F Preferred Stock as follows: Each of the noteholders converted an equity investment incentive in the amount of $13,553 representing 65% of the total amount due under the November 29 Note , along with original principal of $18,750 and accrued interest of $2,101 (a total of $34,404) into 34 shares of the Company’s Series F Preferred Stock. Other than the equity investment incentives of $13,553, there was no gain or loss recognized on this transaction as the Series F Preferred Stock was issued at its face value of $1,000 per share.

 

On September 29, 2023, one of the November 29 Lenders, Sheila Schweitzer, converted her November 29 Note into shares of the Company’s restricted common stock as follows: principal of $18,750 and accrued interest of $2,101 were converted at a price of $0.80 per share into 26,064 shares of the Company’s common stock.

 

On December 8, 2023, pursuant to the Howe debt exchange agreement, Mr. Howe exchanged his note in the principal amount of $18,750 and accrued interest of $2,682 for certain assets of the company. No amounts were due under the Howe note as of December 31, 2023.

 

At December 31, 2023, there was principal and interest in the aggregate amount of $37,500 and $5,903, respectively, due on the two November 29 Notes that are still outstanding. At June 30, 2024, there was principal and interest in the aggregate amount of $37,500 and $7,785, respectively, due on the two November 29 Notes that are still outstanding.

 

Aggregate interest expense as described on the above notes payable – related parties was $15,546 for the six months ended June 30, 2024. Accrued interest on notes payable – related parties were $82,845 and $61,792 at June 30, 2024, and December 31, 2023, respectively.

 

Note 10: Derivative Liabilities

 

Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructuring, and at each period end.

 

Derivative liability activity for the six months ended June 30, 2024, is summarized in the table below:

 

December 31, 2023

  $ 152,945  

True-up features issued

    -  

Settled upon conversion or exercise

    -  

Loss on revaluation

    -  

June 30, 2024

  $ 152,945  

 

The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Volatility

    475.7 %     475.7 %

Stock Price

  $ 0.0250     $ 0.0250  

Risk-free interest rates

    5.21 %     5.21 %

Term (years)

    0.39       0.39  

 

 

Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation:

 

 

The stock price would fluctuate with the Company projected volatility.

 

The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation.

 

The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1.

 

In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions.

 

Discount rates were based on risk-free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

 

Note 11: Stockholders Equity (Deficit)

 

Common Stock

 

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 5,958,582 were issued and outstanding at June 30, 2024.

 

During the six months ended June 30, 2024, the Company issued 90,625 shares of common stock for dividends payable on its Series X Preferred Stock as discussed in further detail below. The price per share used in determining the number of shares issued was $.80, and not the lower price that is called for in the certificate of designation.

 

During the six months ended June 30, 2024, the Company issued 300,000 shares of common stock in aggregate to its advisory board consisting of four (4) individuals, with 75,000 shares issued to each. The Company recorded a compensation expense of $102,500 based on the closing stock price on the date of issuance.

 

Preferred Stock

 

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, 140,000 shares of Series F Preferred, and 31,427 shares as Series X Preferred Stock.

 

Series A Preferred Stock

 

The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at June 30, 2024.

 

Series C Preferred Stock

 

The Series C Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series C ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder. The Company had no shares of Series C Preferred Stock outstanding at June 30, 2024.

 

Series D Preferred Stock

 

The Series D Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series D ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder. The Company had 250,000 shares of Series D Preferred Stock outstanding at June 30, 2024.

 

 

The Company accrued dividends in the amount of $7,855 on the Series D Preferred Stock for the six months ended June 30, 2024. As of June 30, 2024, the Company had $41,654 in accrued dividends on the Series D Preferred Stock.

 

Series E Preferred Stock

 

On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are no shares of Series E Preferred Stock outstanding at June 30, 2024. No shares of Series E Preferred Stock have ever been issued.

 

As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E.

 

Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon.

 

Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.

 

Series F Preferred Stock

 

On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK $0.01 par value Convertible Perpetual Preferred Stock with the Delaware Secretary of State. The number of shares of Series F Preferred Stock designated is 140,000 and each share of Series F Preferred Stock has a liquidation preference of $1,000. The Series F Preferred Stock will rank senior to the Corporation’s Common Stock and on parity with all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank on parity with the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Corporation; and (iii) junior to all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank senior to the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Company.

 

Holders of shares of the Series F Preferred Stock are entitled to receive payment-in-kind dividends payable only in additional shares of Series F Preferred Stock (“PIK Dividends”) at rate of 12% per annum.

 

The Series F Preferred Stock will be convertible into common stock of the Company upon the listing of the Company’s stock on any of the following trading markets: the NYSE, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select Market. The conversion price will be calculated as 65% of the volume-weighted average price of the Company’s common stock on the conversion date. The number of shares issuable upon conversion will be calculated as the liquidation preference of the Series F Preferred stock plus any accrued but unpaid dividends divided by the conversion price.

 

There are 20,057 shares of Series F Preferred Stock outstanding at June 30, 2024

 

On May 17, 2024, the holders of approximately 54.90% of the Series F Preferred shares, having met in person on May 8, 2024, have granted consent to the following modification to the terms of the Series F Preferred, effective May 15, 2024 all dividends, and any obligation to pay dividends shall cease. Any dividends accrued until May 15, 2024, shall be issued as noted in the original certificate of designation.

 

The Company accrued dividends in the amount of $941,713 on the Series F Preferred Stock for the six months ended June 30, 2024. As of June 30, 2024, the Company had $2,497,786 in accrued dividends on the Series F Preferred Stock.

 

 

Series X Preferred Stock

 

The Company has 31,427 and 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of June 30, 2024 and December 31, 2023. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Beginning in July 2023 the Company elected to use a price per share of $.80, a 20% discount to the average price of its common stock of $1.00, before the trading of its common stock was moved to the OTC Expert Market system. This policy has continued through June 30, 2024. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.

 

During the six months ended June 30, 2024, the Company issued 7,200 shares of Series X Preferred Stock to the officers and directors of the compensation in lieu of services in the amount of $180,000 in aggregate, or $60,000 for each of the three (3) directors.

 

On February 9, 2024, the Company issued 41,057 shares of common stock for dividends payable on its Series X Preferred Stock for the period from July 2023 through December 31, 2023, using the $.80 price per share as noted above.

 

On March 20, 2024, the Company issued a total of 25,013 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the first quarter of 2024 using the $.80 price per share as noted above.

 

On June 27, 2024, the Company issued a total of 24,555 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the second quarter of 2024 using the $.80 price per share as noted above.

 

The Company accrued dividends in the amount of $45,886 on the Series X Preferred Stock for the six months ended June 30, 2024. As of June 30, 2024, the Company had $0 in accrued dividends on the Series X Preferred Stock.

 

Stock Options

 

On January 21, 2021, the Company filed a Form S-8 containing the Mitesco Omnibus Securities and Incentive Plan (“the Plan”) with the SEC. In Sections 4.2 and 4.3 of the Plan it is noted that the Board of Directors has the authority for the administration of the Plan. On January 7, 2024, the Board of Directors voted to a) cancel, revoke and terminate any previously issued options that have not already been exercised. For a number of technical reasons, the Plan is no longer valid, and in addition to cancellation of any outstanding options, the Board has voted to formally terminate the Plan.

 

A copy of the Form S-8 which references the Plan can be found at: https://www.sec.gov/Archives/edgar/data/802257/000118518521000098/ex_221520.htm

 

The following table summarizes the options outstanding at June 30, 2024, and the related prices for the options to purchase shares of the Company’s common stock:

 

                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

options

   

contractual

   

outstanding

   

options

   

exercisable

 

prices

   

outstanding

   

life (years)

   

options

   

exercisable

   

options

 
$ 1.50       13,667       5.79     $ 1.50       13,667     $ 1.50  
          13,667       5.79     $ 1.50       13,667     $ 1.50  

 

 

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 

Outstanding at December 31, 2023

    100,934     $ 10.01  

Granted

    -       -  

Cancelled/Expired

    (87,267 )   $ 11.38  

Exercised

    -       -  

Outstanding at June 30, 2024

    13,667     $ 1.50  

Options vested and exercisable

    13,667     $ 1.50  

 

At June 30, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0. At June 30, 2024, there was no intrinsic value on the issued or vested options.

 

Warrants

 

The following table summarizes the warrants outstanding on June 30, 2024, and the related prices for the warrants to purchase shares of the Company’s common stock:

 

                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

warrants

   

contractual

   

outstanding

   

warrants

   

exercisable

 

prices

   

outstanding

   

life (years)

   

warrants

   

exercisable

   

warrants

 
$ 2.50       874       3.81     $ 2.5       874     $ 2.5  
  25.00       366,784       2.23       25.00       366,784       25.00  
  37.50       305,550       2.11       37.50       305,550       37.50  
          673,208       2.17     $ 30.64       673,208     $ 30.64  

 

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding at December 31, 2023

    673,208     $ 30.64  

Granted

    -     $ -  

Exercised

    -     $ -  

Outstanding at June 30, 2024

    673,208     $ 30.64  

 

At June 30, 2024, there was no intrinsic value on the issued or vested options.

 

Note 12: Fair Value of Financial Instruments

 

The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at June 30, 2024, and December 31, 2023.

 

   

June 30, 2024

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  

 

   

December 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  

 

 

Note 13: Commitments and Contingencies

 

Legal

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024, for total consideration consisting of a cash payment of $3,000.

 

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic’s business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

 

Nordhaus Clinic

 

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed.

 

Egan Clinic a.k.a. Vikings

 

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023, and the Company has released the property back to the leaseholder.

 

St. Paul Clinic a.k.a. The Grove

 

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

 

St. Louis Park Clinic a.k.a. Excelsior & Grand

 

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024, and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

 

Eden Prairie Clinic a.k.a. TP Elevate

 

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations for the amounts owed and is in the process of settling the remaining amounts owed.

 

 

Maple Grove Clinic a.k.a. Arbor Lakes

 

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company released the property back to the leaseholder.

 

Radiant Clinic a.k.a. LMC Welton

 

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

 

Quincy Clinic a.k.a. 1776 Curtis

 

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,768

 

 

 

Administrative offices

 

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not received any claims as to the obligations under this sublease agreement and the business from which we were renting has not responded to communications from our attorneys who have attempted to establish a formal settlement agreement since we have abandoned the location more than a year ago.

 

 

Note 14: Subsequent Events

 

On July 18, 2024, in one case, and July 19, 2024, for the other two cases, the Company entered into a lending agreement with each of three (3) of its historical institutional investors, Cavalry Fund, AJB and Mercer Street Capital (“the Lenders”). The notes provide $25,000 of proceeds each, are for a 12-month period, and earn interest at ten percent (10%) per year.

 

On July 29, 2024, the Board of Directors approved a consulting agreement which was effective July 8, 2024, with Brian Valania, to manage sales and marketing for the Centcore, LLC business unit. Mr. Valania replaces Ms. Betsy Berlin who was engaged in May 2024 and terminated by mutual consent in June 2024, with a total cost of $10,000. His compensation includes a monthly fee of $11,250, and additional compensation to be determined based on the achievement of certain business goals of up to $135,000 per year. He was also issued 200,000 shares of restricted common stock of which 100,000 is considered immediately earned, 50,000 are considered earned as of December 31, 2024, and the final 50,000 are considered earned as of June 30, 2024. His continued employment is among the conditions for earning the shares discussed herein. The Company will realize a charge of $50,000 in the 3rd quarter of 2024 for this issuance, which was expensed at $.25 per share.

 

On July 29, 2024, the Company issued 100,000 of restricted common stock to each of its three (3) directors in consideration of their contribution to operations beyond the scope of their responsibilities on the Board. The issuance of 300,000 shares in aggregate will result in a charge during the 3rd quarter of 2024 of $75,000 in total, using a valuation of $.25 per share.

 

 

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

References to the Company, Mitesco, Inc., our, us or we refer to Mitesco, Inc. The following discussion and analysis of the Companys financial condition and results of operations should be read in conjunction with the unaudited interim financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, could, would, expect, plan, anticipate, believe, estimate, continue, or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

 

History and Outlook

 

We are a holding company seeking to provide products, services and technology. From 2020 through 2022, the Company was executing against a strategic plan to open primary care clinics utilizing advanced degreed nurse practitioners in select markets. The clinics operated under the name The Good Clinic. However, the business failed to achieve profitability, and the markets were not favorable to additional funding, therefore in late 2022 the decision was made to close the clinics and release all employees.

 

We are a holding company seeking to provide products, services and technology. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS).

 

In June 2024 we announced the formation of two (2) new wholly owned business units, Centcore, LLC, who is providing data center services including cloud computing and application hosting, and Vero Technology Ventures, LLC, whose aim is to seek investment and acquisition opportunities, generally in the areas of cloud computing and data center related applications.

 

Centcore has two (2) areas of focus. The first, generic data center services, is aimed at hosting applications for a specific user, sometimes referred to as “managed services offerings” or MSO, where the client moves the software licensed from various vendors, or internally developed, into our data center where we maintain the computing, communications and backup environment. The second focus involves hosting application software developed by software vendors, from which they will sell the use of the software by their end user clients on a “cloud” basis. By taking this approach we gain the business of the vendor, and their clients, perhaps allowing us to grow at a faster rate with lower cost of sales. We have developed the “Centcore Partner Program” where we will help promote the software vendors who are hosting in our data centers. If we are successful helping the vendor grow his business, we will have provided a “value added service”, and benefit from increased utilization of our computing resources by not only the vendor, but also his new end user clients. Our initial focus for this area is on software providers who serve the “infrastructure” market doing design, engineering, construction and maintenance of significant assets. We desire to create “life cycle” relationships with both the design teams, and owners which may include private owners such as manufacturers and utilities, or publicly owned assets for municipalities, states or federal governments, domestically and internationally.

 

We have retained proven professionals in the data center, cyber security and infrastructure services areas to support our needs on a per hour basis, which we believe will allow us to control our costs relative to business activity, without significant staffing internally.

 

Results of Operations

 

The following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period of any future periods. Results of discontinued operations are excluded from the accompanying results of operations for all periods presented, unless otherwise noted. See Note 3 – discontinued operations in the accompanying notes to consolidated financial statements. Further, as a result of any acquisitions of other businesses, and any additional pharmacy acquisitions or other such transactions we may pursue, we may experience large expenditures specific to the transactions that are not incident to our operations.

 

 

Comparison of the Three Months Ended June 30, 2024, and 2023.

 

Revenues

 

We had revenues of $6,000 for the three months ended June 30, 2024, compared to $0 in the comparable period. The revenues were related to our newly formed subsidiary Centcore, LLC.

 

Operating Expenses

 

Our total operating expenses for the three months ended June 30, 2024, were $345,877. For the comparable period in 2023, the operating expenses were $558,277. The decrease is the result of the winding down of the Company’s clinic operations with The Good Clinic, LLC subsidiary.

 

Other Income and Expenses

 

Interest expense was $67,603 for the three months ended June 30, 2024, compared to 129,436 for the three months ended June 30, 2023. The decrease was a result of reduced debt balances in the current period.

 

Interest expense – related parties was $4,965 for the three months ended June 30, 2024, compared to $29,954 in the prior period. The decrease was a result of reduced debt balances in the current period.

 

During the three months ended June 30, 2023, we recorded equity investment incentives of approximately $6.4 million. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a gain on forgiveness of debt of $25,000. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a gain on sale of assets of $20,097. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a gain on issuance of shares to a service provider of $33,092. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a loss on settlement of true-up obligation of $119,370. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a loss on legal settlement of $18,759. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a gain on revaluation of derivative liabilities of $39,738. There were no comparable transactions in the current period.

 

For the three months ended June 30, 2024, we had a net loss available to common shareholders from discontinued operations of $0, compared to a net loss available to common shareholders from discontinued operations of $373,759.

 

Comparison of the Six Months Ended June 30, 2024, and 2023.

 

Revenues

 

We had revenues of $6,000 for the six months ended June 30, 2024, compared to $0 in the comparable period. The revenues were related to our newly formed subsidiary Centcore, LLC.

 

Operating Expenses

 

Our total operating expenses for the six months ended June 30, 2024, were $481,353. For the comparable period in 2023, the operating expenses were $2,188,180. The decrease is the result of the winding down of the Company’s clinic operations with The Good Clinic, LLC subsidiary.

 

 

Other Income and Expenses

 

Interest expense was $108,227 for the six months ended June 30, 2024, compared to 1,505,502 for the six months ended June 30, 2023. The decrease was a result of reduced debt balances in the current period.

 

Interest expense – related parties was $15,546 for the six months ended June 30, 2024, compared to $73,523 in the prior period. The decrease was a result of reduced debt balances in the current period.

 

During the six months ended June 30, 2024, we recorded a gain on termination of operating lease of approximately $233,000. There were no comparable transactions in the prior period.

 

During the six months ended June 30, 2023, we recorded equity investment incentives of approximately $6.4 million. There were no comparable transactions in the current period.

 

During the six months ended June 30, 2023, we recorded a gain on forgiveness of debt of $25,000. There were no comparable transactions in the current period.

 

During the six months ended June 30, 2023, we recorded a gain on sale of assets of $20,097. There were no comparable transactions in the current period.

 

During the six months ended June 30, 2023, we recorded a gain on issuance of shares to a service provider of $33,092. There were no comparable transactions in the current period.

 

During the six months ended June 30, 2023, we recorded a loss on settlement of true-up obligation of $119,370. There were no comparable transactions in the current period.

 

During the three months ended June 30, 2023, we recorded a loss on legal settlement of $18,759. There were no comparable transactions in the current period.

 

During the six months ended June 30, 2023, we recorded a loss on revaluation of derivative liabilities of $71,040. There were no comparable transactions in the current period.

 

For the three months ended June 30, 2024, we had a net loss available to common shareholders from discontinued operations of $0, compared to a net loss available to common shareholders from discontinued operations of $2,698,803.

 

Liquidity and Capital Resources

 

To date, we have not generated sufficient revenue from operations to support our operations. We have financed our operations through the sale of equity securities and short-term borrowings. As of August [ ], 2024, we had cash of approximately $[ ] compared to cash of approximately $40,000 as of June 30, 2024. Our Company’s recurring losses from operations and negative cash flows from operations and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern.

 

Net cash used in operating activities was $248,157 for the six months ended June 30, 2024. This is the result of the winding down of the Company’s clinic operations. Cash used in operations for the six months ended June 30, 2023, was $518,232.

 

The Company had no investing activities for the six months ended June 30, 2024, and 2023.

 

Net cash provided by financing activities for the six months ended June 30, 2024, was $285,515, compared to $738,500 for the six months ended June 30, 2023. Cash provided by financing activities was the result of cash proceeds from notes payable, offset by the repayment of principal on the SBA loan in the amount of $7,786.

 

At June 30, 2024, we had the following current liabilities which are payable in cash: Accounts payable and accrued liabilities of $7.4 million; notes payable of $1.2 million; notes payable to related parties of $.3 million; SBA Loan Payable of $0.4 million; legal settlements of $2.5 million; accrued interest payable of $0.4 million; accrued interest payable to related parties of $0.01 million; and other current liabilities of $0.1 million. We also have the following liabilities which are payable in stock: derivative liabilities of $0.2 million, preferred stock dividends of $2.3 million, and preferred stock dividends payable to related parties of $0.2 million.

 

 

We have agreements from three (3) of our institutional investors to provide interim funding so that the Company may stay current with its accounting and reporting requirements under the Securities Act of 1934, settle obligations from the prior healthcare clinic operations and find a new business area to engage within. The team performing the work effort is doing so with no cash compensation, either paid or accrued. Through June 30, 2024, the total amount loaned under 12-month, 10% interest simple notes is $300,000, with roughly $200,000 attributable to accounting and compliance, $50,000 generally related to settlements and legal related, with the remaining for general expenses including T&E and communications.

 

In May 2024 we reached an agreement with the holders of our Series F Preferred shares to waive all interest payments permanently beginning May 15, 2024. This creates a reduction in accrued interest of over $200,000 per month. Similar adjustments with other holders of debt and interest paying equity are expected.

 

The Company is working with its institutional investors on a plan to eliminate all existing obligations through the issuance of a new preferred stock which would be issued to the holder in lieu of debt. It is envisioned that this stock would be listed and traded separately from the Company’s common stock. This plan is in its early stages and there can be no guarantee that it will be fully implemented, approved by the SEC for trading, or accepted by all creditors, some of which may be required to see a reduction in the amounts currently owned in order to get consent from the larger investor group.

 

The Company has relationships with a number of consultants who are assisting in the creation of the new business units. It is anticipated that this approach will continue indefinitely as it does not desire to create the overhead associated with a large employment force.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,786

 

 

 

Critical Accounting Estimates

 

Management uses various estimates and assumptions in preparing our financial statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Accounting estimates that are the most important to the presentation of our results of operations and financial condition, and which require the greatest use of judgment by management, are designated as our critical accounting estimates. We have the following critical accounting estimates:

 

 

Estimates and assumptions used in the valuation of derivative liabilities: Management utilizes a lattice model to estimate the fair value of derivative liabilities. The model includes subjective assumptions that can materially affect the fair value estimates.

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

(a) Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such an evaluation, the Company’s management has identified what it believes are material weaknesses in the Company’s disclosure controls and procedures and concluded that we did not have effective disclosure controls and procedures.

 

The deficiencies in our disclosure controls and procedures included (i) lack of segregation of duties and (ii) lack of sufficient resources to ensure that information required to be disclosed by the Company in the reports that the Company files or submits to the SEC are recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms.

 

The Company intends to take corrective action to ensure that information required to be disclosed by the Company pursuant to the reports that the Company files or submits to the SEC is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

(b) Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the six months ended June 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024, for total consideration consisting of a cash payment of $3,000.

 

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic’s business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

 

Nordhaus Clinic

 

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed.

 

Egan Clinic a.k.a. Vikings

 

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023, and the Company has released the property back to the leaseholder.

 

St. Paul Clinic a.k.a. The Grove

 

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

 

St. Louis Park Clinic a.k.a. Excelsior & Grand

 

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024, and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

 

Eden Prairie Clinic a.k.a. TP Elevate

 

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations for the amounts owed and is in the process of settling the remaining amounts owed.

 

 

Maple Grove Clinic a.k.a. Arbor Lakes

 

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company released the property back to the leaseholder.

 

Radiant Clinic a.k.a. LMC Welton

 

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

 

Quincy Clinic a.k.a. 1776 Curtis

 

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,768

 

 

 

Administrative offices

 

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not entered into a settlement agreement on this site as of the date of this filing but expect to shortly.

 

ITEM 1A. RISK FACTORS

 

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 16, 2024. There have been no material changes to the risk factors described in that report.

 

 

ITEM 2. SALE OF UNREGISTERED SECURITIES

 

Common Stock

 

On June 27, 2024, the Company issued a total of 24,555 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the second quarter of 2024 using the $.80 price per share as noted above.

 

During the six months ended June 30, 2024, the Company issued 300,000 shares of common stock to its advisory council. The Company recorded a compensation expense of $102,500 based on the closing stock price on the date of issuance.

 

ITEM 3. DEFAULTS ON SENIOR SECURED SECURITIES

 

Not Applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION

 

Not Applicable.

 

ITEM 6. EXHIBITS

 

The following exhibits are included with this Quarterly Report on Form 10-Q.

 

 

 

 

 

Form

Type

 

Exhibit

Number

 

Date

Filed

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Certificate of Incorporation of Trunity Holdings, Inc., dated January 18, 2012.

 

8-K

 

10.1

 

1/31/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Bylaws of Trunity Holdings, Inc., dated January 18, 2012.

 

8-K

 

10.2

 

1/31/2012

 

 

 

 

 

 

 

 

 

 

 

 

 

3.3

 

Certificate of Ownership Merging between Trunity Holdings, Inc. and Brain Tree International, Inc. dated January 24, 2012.

 

10-K

 

3.3

 

4/16/2013

 

 

 

 

 

 

 

 

 

 

 

 

 

3.4

 

Certificate of Amendment to the Certificate of Incorporation of Trunity Holdings, Inc., dated December 24, 2015.

 

8-K

 

3.1(i)

 

1/06/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

3.5

 

Certificate of Designations of Series X Preferred Stock of True Nature Holding, Inc.

 

8-K

 

3.6

 

1/06/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.6

 

Form of Amended and Restated Certificate of Designations of Series A Preferred Stock of True Nature Holding, Inc.

 

8-K

 

3.07

 

3/13/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.7

 

Certificate of Amendment of the Certificate of Incorporation of True Nature Holding, Inc. dated April 21, 2020.

 

10-Q

 

3.7

 

8/14/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.8

 

Certificate of Amendment of Certificate of Incorporation, dated as of November 5, 2020, correcting December 24, 2015, Certificate of Amendment.

 

10-Q

 

3.8

 

11/13/2020

 

 

 

 

 

 

 

 

Form

Type

 

Exhibit

Number

 

Date

Filed

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

3.9

 

Bylaws of Mitesco, Inc., as amended, dated November 10, 2020

 

10-Q

 

3.9

 

11/13/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

3.10

 

Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.

 

8-K

 

3.1

 

03/26/2021

 

 

 

 

 

 

 

 

 

 

 

 

 

3.11

 

Certificate of Correction to the Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock of Mitesco, Inc.

 

8-K

 

3.2

 

03/26/2021

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification by the Principal Executive Officer of the Registrant pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification by the Principal Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.INS **

 

XBRL INSTANCE DOCUMENT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH **

 

XBRL TAXONOMY EXTENSION SCHEMA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL **

 

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF **

 

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB **

 

XBRL TAXONOMY EXTENSION LABEL LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE **

 

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

#

 

 

Management contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report.

 

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q for the period ended June 30, 2024, to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

MITESCO, INC.

 

 

 

 

Dated: August 14, 2024

By:

/s/ Mack Leath

 

 

 

Mack Leath

Chief Executive Officer, Chief Financial Officer and Principal Financial Officer

 

 

37
false --12-31 Q2 0000802257 0000802257 2024-01-01 2024-06-30 0000802257 2024-08-14 0000802257 2024-06-30 0000802257 2023-12-31 0000802257 us-gaap:NonrelatedPartyMember 2024-06-30 0000802257 us-gaap:NonrelatedPartyMember 2023-12-31 0000802257 us-gaap:RelatedPartyMember 2024-06-30 0000802257 us-gaap:RelatedPartyMember 2023-12-31 0000802257 us-gaap:SeriesAPreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesAPreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesCPreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesCPreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesDPreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesFPreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesFPreferredStockMember 2023-12-31 0000802257 miti:SeriesXPreferredStockMember 2024-06-30 0000802257 miti:SeriesXPreferredStockMember 2023-12-31 0000802257 2024-04-01 2024-06-30 0000802257 2023-04-01 2023-06-30 0000802257 2023-01-01 2023-06-30 0000802257 us-gaap:NonrelatedPartyMember 2024-04-01 2024-06-30 0000802257 us-gaap:NonrelatedPartyMember 2023-04-01 2023-06-30 0000802257 us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0000802257 us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0000802257 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0000802257 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0000802257 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0000802257 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000802257 us-gaap:CommonStockMember 2023-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000802257 us-gaap:RetainedEarningsMember 2023-12-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2024-01-01 2024-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000802257 2024-01-01 2024-03-31 0000802257 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000802257 us-gaap:CommonStockMember 2024-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000802257 us-gaap:RetainedEarningsMember 2024-03-31 0000802257 2024-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2024-04-01 2024-06-30 0000802257 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000802257 miti:SeriesXPreferredStockMember miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000802257 miti:SeriesXPreferredStockMember 2024-04-01 2024-06-30 0000802257 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000802257 us-gaap:CommonStockMember 2024-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000802257 us-gaap:RetainedEarningsMember 2024-06-30 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000802257 us-gaap:CommonStockMember 2022-12-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000802257 miti:StockSubscribedMember 2022-12-31 0000802257 us-gaap:RetainedEarningsMember 2022-12-31 0000802257 2022-12-31 0000802257 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000802257 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000802257 2023-01-01 2023-03-31 0000802257 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2023-01-01 2023-03-31 0000802257 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000802257 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000802257 us-gaap:CommonStockMember 2023-03-31 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000802257 miti:StockSubscribedMember 2023-03-31 0000802257 us-gaap:RetainedEarningsMember 2023-03-31 0000802257 2023-03-31 0000802257 us-gaap:CommitmentsMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:CommitmentsMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 us-gaap:CommitmentsMember 2023-04-01 2023-06-30 0000802257 miti:TrueupAgreementMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000802257 miti:TrueupAgreementMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 miti:TrueupAgreementMember 2023-04-01 2023-06-30 0000802257 miti:LegalSettlementMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000802257 miti:LegalSettlementMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 miti:LegalSettlementMember 2023-04-01 2023-06-30 0000802257 miti:SharesPreviouslySubscribedMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000802257 miti:SharesPreviouslySubscribedMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 miti:SharesPreviouslySubscribedMember miti:StockSubscribedMember 2023-04-01 2023-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 miti:StockIssuedForDividendsPayableMember miti:SeriesXPreferredStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 us-gaap:AccountsPayableMember us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:AccountsPayableMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 us-gaap:AccountsPayableMember 2023-04-01 2023-06-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember us-gaap:SeriesFPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember us-gaap:SeriesFPreferredStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:ConvertibleDebtMember us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:ConvertibleDebtMember us-gaap:SeriesFPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000802257 us-gaap:ConvertibleDebtMember us-gaap:SeriesFPreferredStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000802257 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000802257 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000802257 miti:SeriesXPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000802257 us-gaap:CommonStockMember 2023-06-30 0000802257 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000802257 us-gaap:RetainedEarningsMember 2023-06-30 0000802257 2023-06-30 0000802257 miti:StockSubscribedMember 2024-01-01 2024-06-30 0000802257 miti:StockSubscribedMember 2023-01-01 2023-06-30 0000802257 us-gaap:AccountsPayableMember 2024-01-01 2024-06-30 0000802257 us-gaap:AccountsPayableMember 2023-01-01 2023-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember 2024-01-01 2024-06-30 0000802257 miti:SeriesCAndSeriesDPreferredSharesMember 2023-01-01 2023-06-30 0000802257 us-gaap:SeriesFPreferredStockMember 2024-01-01 2024-06-30 0000802257 us-gaap:SeriesFPreferredStockMember 2023-01-01 2023-06-30 0000802257 us-gaap:WarrantMember 2024-04-01 2024-06-30 0000802257 us-gaap:WarrantMember 2024-01-01 2024-06-30 0000802257 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0000802257 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-04-01 2024-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-01-01 2024-06-30 0000802257 us-gaap:WarrantMember 2023-04-01 2023-06-30 0000802257 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000802257 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000802257 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2023-04-01 2023-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-06-30 0000802257 2023-12-08 2023-12-08 0000802257 miti:PPPLoanMember 2020-05-04 0000802257 2023-07-12 2023-07-12 0000802257 2023-07-12 0000802257 miti:PPPLoanMember 2023-01-01 2023-12-31 0000802257 miti:PPPLoanMember 2023-12-31 0000802257 miti:PPPLoanMember 2024-01-01 2024-06-30 0000802257 miti:PPPLoanMember miti:AccruedInterestMember 2024-01-01 2024-06-30 0000802257 miti:KishonNoteMember 2022-05-10 2022-05-10 0000802257 miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember miti:OriginalIssueDiscountMember 2022-05-10 0000802257 srt:MinimumMember miti:KishonNoteMember 2022-05-10 0000802257 miti:KishonNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-05-10 0000802257 miti:KishonNoteMember miti:DefaultPenaltyMember 2023-12-31 0000802257 miti:KishonNoteMember 2023-12-31 0000802257 miti:KishonNoteMember 2024-06-30 0000802257 miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:FinneganNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-23 0000802257 miti:WarrantsAt2500Member miti:FinneganNote1Member 2022-05-23 2022-05-23 0000802257 miti:WarrantsAt2500Member miti:FinneganNote1Member 2022-05-23 0000802257 miti:FinneganNote1Member 2023-12-31 0000802257 miti:FinneganNote1Member 2024-06-30 0000802257 miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:FinneganNote2Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:FinneganNote2Member 2022-05-26 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:FinneganNote2Member 2022-05-26 0000802257 miti:FinneganNote2Member 2023-12-31 0000802257 miti:FinneganNote2Member 2024-06-30 0000802257 miti:SchrierNoteMember 2022-07-07 0000802257 miti:SchrierNoteMember 2022-07-07 2022-07-07 0000802257 miti:SchrierNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-07 0000802257 miti:WarrantsAt2500Member miti:SchrierNoteMember 2022-07-07 0000802257 miti:SchrierNoteMember 2023-12-31 0000802257 miti:SchrierNoteMember 2024-06-30 0000802257 miti:NommsenNoteMember 2022-07-26 0000802257 miti:NommsenNoteMember 2022-07-26 2022-07-26 0000802257 miti:NommsenNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-26 0000802257 miti:WarrantsAt2500Member miti:NommsenNoteMember 2022-07-26 2022-07-26 0000802257 miti:WarrantsAt2500Member miti:NommsenNoteMember 2022-07-26 0000802257 miti:NommsenNoteMember 2023-12-31 0000802257 miti:NommsenNoteMember 2024-06-30 0000802257 miti:CaplanNoteMember 2022-07-27 0000802257 miti:CaplanNoteMember 2022-07-27 2022-07-27 0000802257 miti:CaplanNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-07-27 0000802257 miti:WarrantsAt2500Member miti:CaplanNoteMember 2022-07-27 2022-07-27 0000802257 miti:WarrantsAt2500Member miti:CaplanNoteMember 2022-07-27 0000802257 miti:CaplanNoteMember 2023-12-31 0000802257 miti:CaplanNoteMember 2024-06-30 0000802257 miti:FinneganNote3Member 2022-08-04 0000802257 miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:FinneganNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-08-04 0000802257 miti:WarrantsAt2500Member miti:FinneganNote3Member 2022-08-04 2022-08-04 0000802257 miti:WarrantsAt2500Member miti:FinneganNote3Member 2022-08-04 0000802257 miti:FinneganNote3Member 2023-12-31 0000802257 miti:FinneganNote3Member 2024-06-30 0000802257 miti:LightmasNoteMember 2022-09-02 0000802257 miti:LightmasNoteMember 2022-09-02 2022-09-02 0000802257 miti:LightmasNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:LightmasNoteMember 2023-12-31 0000802257 miti:LightmasNoteMember 2024-06-30 0000802257 miti:LewisNoteMember 2022-09-02 0000802257 miti:LewisNoteMember 2022-09-02 2022-09-02 0000802257 miti:LewisNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:LewisNoteMember 2023-12-31 0000802257 miti:LewisNoteMember 2024-06-30 0000802257 miti:GoffNoteMember 2022-09-02 0000802257 miti:GoffNoteMember 2022-09-02 2022-09-02 0000802257 miti:GoffNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:GoffNoteMember 2023-12-31 0000802257 miti:GoffNoteMember 2024-06-30 0000802257 miti:HaganNoteMember 2022-09-02 0000802257 miti:HaganNoteMember 2022-09-02 2022-09-02 0000802257 miti:HaganNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-02 0000802257 miti:HaganNoteMember 2023-12-31 0000802257 miti:HaganNoteMember 2024-06-30 0000802257 miti:CavalryNote1Member 2024-01-23 0000802257 miti:CavalryNote1Member us-gaap:MeasurementInputDefaultRateMember 2024-01-23 0000802257 miti:CavalryNote1Member 2024-06-30 0000802257 miti:CavalryNote2Member 2024-02-28 0000802257 miti:CavalryNote2Member us-gaap:MeasurementInputDefaultRateMember 2024-02-28 0000802257 miti:CavalryNote2Member 2024-06-30 0000802257 miti:CavalryNote3Member 2024-05-13 0000802257 miti:CavalryNote3Member 2024-05-13 2024-05-13 0000802257 miti:CavalryNote3Member us-gaap:MeasurementInputDefaultRateMember 2024-05-13 0000802257 miti:CavalryNote3Member 2024-06-30 0000802257 miti:MercerNote1Member 2024-01-23 0000802257 miti:MercerNote1Member 2024-01-23 2024-01-23 0000802257 miti:MercerNote1Member us-gaap:MeasurementInputDefaultRateMember 2024-01-23 0000802257 miti:MercerNote1Member 2024-06-30 0000802257 miti:MercerNote2Member 2024-02-28 0000802257 miti:MercerNote2Member 2024-02-28 2024-02-28 0000802257 miti:MercerNote2Member us-gaap:MeasurementInputDefaultRateMember 2024-02-28 0000802257 miti:MercerNote2Member 2024-06-30 0000802257 miti:MercerNote3Member 2024-05-13 0000802257 miti:MercerNote3Member 2024-05-13 2024-05-13 0000802257 miti:MercerNote3Member us-gaap:MeasurementInputDefaultRateMember 2022-09-15 0000802257 miti:MercerNote3Member 2024-06-30 0000802257 miti:AJBCapitalNote1Member 2024-02-28 0000802257 miti:AJBCapitalNote1Member 2024-02-28 2024-02-28 0000802257 miti:AJBCapitalNote1Member us-gaap:MeasurementInputDefaultRateMember 2024-02-28 0000802257 miti:AJBCapitalNote1Member 2024-06-30 0000802257 miti:AJBCapitalNote2Member 2024-05-15 0000802257 miti:AJBCapitalNote2Member 2024-05-15 2024-05-15 0000802257 miti:AJBCapitalNote2Member us-gaap:MeasurementInputDefaultRateMember 2024-05-15 0000802257 miti:AJBCapitalNote2Member 2024-06-30 0000802257 us-gaap:NotesPayableOtherPayablesMember 2024-06-30 0000802257 us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0000802257 miti:CavalryNote1Member 2023-12-31 0000802257 miti:CavalryNote2Member 2023-12-31 0000802257 miti:MercerNote1Member 2023-12-31 0000802257 miti:MercerNote2Member 2023-12-31 0000802257 miti:AJBCapitalNoteMember 2024-06-30 0000802257 miti:AJBCapitalNoteMember 2023-12-31 0000802257 miti:CavalryNote3Member 2023-12-31 0000802257 miti:MercerNote3Member 2023-12-31 0000802257 miti:AJBCapitalNote2Member 2023-12-31 0000802257 miti:MDiamondNoteMember 2022-05-26 0000802257 miti:MDiamondNoteMember 2022-05-26 2022-05-26 0000802257 miti:MDiamondNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:MDiamondNoteMember 2022-05-26 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:MDiamondNoteMember 2022-05-26 0000802257 miti:MDiamondNoteMember 2023-12-31 0000802257 miti:MDiamondNoteMember 2024-06-30 0000802257 miti:DobbertinNote1Member 2022-05-26 0000802257 miti:DobbertinNote1Member 2022-05-26 2022-05-26 0000802257 miti:DobbertinNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:DobbertinNote1Member 2022-05-26 0000802257 miti:DobbertinNote1Member 2023-12-31 0000802257 miti:DobbertinNote1Member 2024-06-30 0000802257 miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote1Member 2022-05-26 2022-05-26 0000802257 miti:LindstromNote1Member us-gaap:MeasurementInputDefaultRateMember 2022-05-26 0000802257 miti:WarrantsAt2500Member miti:LindstromNote1Member 2022-05-26 0000802257 miti:LindstromNote1Member 2023-12-31 0000802257 miti:LindstromNote1Member 2024-06-30 0000802257 miti:MitchellNoteMember 2022-06-09 0000802257 miti:MitchellNoteMember 2022-06-09 2022-06-09 0000802257 miti:MitchellNoteMember 2021-12-30 2021-12-30 0000802257 miti:MitchellNoteMember 2021-12-30 0000802257 miti:MitchellNoteMember us-gaap:MeasurementInputDefaultRateMember 2021-12-30 0000802257 miti:MitchellNoteMember miti:WarrantsAt2500Member 2021-12-30 2021-12-30 0000802257 miti:MitchellNoteMember 2023-12-31 0000802257 miti:MitchellNoteMember 2024-06-30 0000802257 miti:LeathNoteMember 2022-09-15 0000802257 miti:LeathNoteMember 2022-09-15 2022-09-15 0000802257 miti:LeathNoteMember us-gaap:MeasurementInputDefaultRateMember 2022-09-15 0000802257 miti:LeathNoteMember 2023-12-31 0000802257 miti:LeathNoteMember 2024-06-30 0000802257 miti:November292022NotesMember 2022-11-29 2022-11-29 0000802257 miti:November292022NotesMember us-gaap:MeasurementInputDefaultRateMember 2022-11-29 0000802257 miti:November292022NotesMember 2022-01-01 2022-12-31 0000802257 miti:November292022NotesMember 2022-12-31 0000802257 miti:November292022NotesMember 2023-01-01 2023-12-31 0000802257 miti:InvestmentIncentiveMember miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 us-gaap:ConvertibleNotesPayableMember miti:November292022NotesMember us-gaap:SeriesFPreferredStockMember 2023-09-29 2023-09-29 0000802257 miti:AccruedInterestMember miti:November292022NotesMember us-gaap:SeriesFPreferredStockMember 2023-09-29 2023-09-29 0000802257 miti:November292022NotesMember us-gaap:SeriesFPreferredStockMember 2023-09-29 2023-09-29 0000802257 miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 us-gaap:ConvertibleNotesPayableMember miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 miti:AccruedInterestMember miti:November292022NotesMember 2023-09-29 2023-09-29 0000802257 miti:November292022NotesMember 2023-09-29 0000802257 us-gaap:ConvertibleNotesPayableMember miti:HoweNoteMember 2023-12-08 2023-12-08 0000802257 miti:AccruedInterestMember miti:HoweNoteMember 2023-12-08 2023-12-08 0000802257 miti:November292022NotesMember 2023-12-31 0000802257 miti:November292022NotesMember 2024-06-30 0000802257 miti:MDiamondNoteMember us-gaap:RelatedPartyMember 2024-06-30 0000802257 miti:MDiamondNoteMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:DobbertinNote1Member us-gaap:RelatedPartyMember 2024-06-30 0000802257 miti:DobbertinNote1Member us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:LindstromNote1Member us-gaap:RelatedPartyMember 2024-06-30 0000802257 miti:LindstromNote1Member us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:MitchellNoteMember us-gaap:RelatedPartyMember 2024-06-30 0000802257 miti:MitchellNoteMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:LeathNoteMember us-gaap:RelatedPartyMember 2024-06-30 0000802257 miti:LeathNoteMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 miti:November292022NotesMember us-gaap:RelatedPartyMember 2024-06-30 0000802257 miti:November292022NotesMember us-gaap:RelatedPartyMember 2023-12-31 0000802257 2023-01-01 2023-12-31 0000802257 us-gaap:SeriesEPreferredStockMember 2024-06-30 0000802257 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-06-30 0000802257 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-06-30 0000802257 us-gaap:SeriesDPreferredStockMember 2024-01-01 2024-06-30 0000802257 us-gaap:SeriesEPreferredStockMember 2022-11-07 2022-11-07 0000802257 us-gaap:SeriesEPreferredStockMember 2022-11-07 0000802257 us-gaap:SeriesFPreferredStockMember 2023-03-23 0000802257 miti:SeriesXPreferredStockMember 2024-01-01 2024-06-30 0000802257 miti:SeriesXPreferredStockMember 2023-07-01 0000802257 miti:SeriesXPreferredStockMember 2023-07-01 2023-07-01 0000802257 us-gaap:CommonStockMember 2023-07-01 0000802257 miti:OfficersAndDirectorsMember miti:SeriesXPreferredStockMember 2024-01-01 2024-06-30 0000802257 srt:DirectorMember miti:SeriesXPreferredStockMember 2024-01-01 2024-06-30 0000802257 miti:SeriesXPreferredStockMember 2024-02-09 2024-02-09 0000802257 miti:SeriesXPreferredStockMember 2024-02-09 0000802257 miti:SeriesXPreferredStockMember 2024-03-20 2024-03-20 0000802257 miti:SeriesXPreferredStockMember 2024-03-20 0000802257 miti:SeriesXPreferredStockMember 2024-06-27 2024-06-27 0000802257 miti:SeriesXPreferredStockMember 2024-06-27 0000802257 us-gaap:EmployeeStockOptionMember 2024-06-30 0000802257 miti:RangeOfExercisePrice2.50Member 2024-06-30 0000802257 miti:RangeOfExercisePrice2.50Member 2024-01-01 2024-06-30 0000802257 miti:RangeOfExercisePrice25.00Member 2024-06-30 0000802257 miti:RangeOfExercisePrice25.00Member 2024-01-01 2024-06-30 0000802257 miti:RangeOfExercisePrice37.50Member 2024-06-30 0000802257 miti:RangeOfExercisePrice37.50Member 2024-01-01 2024-06-30 0000802257 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000802257 us-gaap:FairValueInputsLevel2Member 2024-06-30 0000802257 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000802257 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000802257 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000802257 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000802257 2024-01-11 2024-01-11 0000802257 us-gaap:RestrictedStockMember us-gaap:SettledLitigationMember 2022-10-25 2022-10-25 0000802257 miti:CEOOfTheGoodClinicMember us-gaap:RestrictedStockMember us-gaap:SettledLitigationMember 2022-10-25 2022-10-25 0000802257 2022-10-25 2022-10-25 0000802257 2020-11-01 0000802257 2021-10-14 0000802257 us-gaap:JudicialRulingMember 2023-12-15 2023-12-15 0000802257 2023-12-15 0000802257 us-gaap:JudicialRulingMember 2023-12-21 2023-12-21 0000802257 2021-05-04 0000802257 us-gaap:JudicialRulingMember 2024-04-02 2024-04-02 0000802257 2021-06-08 0000802257 2021-10-08 0000802257 us-gaap:JudicialRulingMember 2022-10-22 2022-10-22 0000802257 2021-09-21 0000802257 us-gaap:SettledLitigationMember 2024-04-10 2024-04-10 0000802257 2021-09-28 0000802257 us-gaap:JudicialRulingMember 2023-11-14 2023-11-14 0000802257 2023-11-14 0000802257 miti:NordhausMinneapolisMNMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:NordhausMinneapolisMNMember 2024-06-30 0000802257 miti:ProminadeWayzettaMNMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:ProminadeWayzettaMNMember 2024-06-30 0000802257 miti:EaganClinicEaganMNMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:EaganClinicEaganMNMember 2024-06-30 0000802257 miti:ExcelsiorGrandStLouisParkMNMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:ExcelsiorGrandStLouisParkMNMember 2024-06-30 0000802257 miti:TheGroveStPaulMNMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:TheGroveStPaulMNMember 2024-06-30 0000802257 miti:ElevateEdenPrarieMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:ElevateEdenPrarieMember 2024-06-30 0000802257 miti:ArborLakesMapleGraveMNMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:ArborLakesMapleGraveMNMember 2024-06-30 0000802257 miti:LMCWeltonDenverCOMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:LMCWeltonDenverCOMember 2024-06-30 0000802257 miti:Curtis1776DenverCOMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember miti:Curtis1776DenverCOMember 2024-06-30 0000802257 us-gaap:SettledLitigationMember 2024-06-30 0000802257 miti:CavalryFundNoteMember us-gaap:SubsequentEventMember 2024-07-18 2024-07-18 0000802257 miti:AJBNoteMember us-gaap:SubsequentEventMember 2024-07-19 2024-07-19 0000802257 miti:MercerStreetCapitalMember us-gaap:SubsequentEventMember 2024-07-19 2024-07-19 0000802257 miti:CavalryFundNoteMember us-gaap:SubsequentEventMember 2024-07-18 0000802257 miti:AJBNoteMember us-gaap:SubsequentEventMember 2024-07-19 0000802257 miti:MercerStreetCapitalMember us-gaap:SubsequentEventMember 2024-07-19 0000802257 us-gaap:SubsequentEventMember 2024-07-29 2024-07-29 0000802257 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2024-07-01 2024-09-30 0000802257 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember 2024-09-30 0000802257 miti:ThreeDirectorMember us-gaap:SubsequentEventMember 2024-07-29 2024-07-29 0000802257 srt:DirectorMember us-gaap:SubsequentEventMember 2024-07-29 2024-07-29 0000802257 us-gaap:SubsequentEventMember 2024-07-01 2024-09-30 0000802257 us-gaap:SubsequentEventMember 2024-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, Mack Leath, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Mitesco, Inc.;

 

2.

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

d)

Disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: August 14, 2024

 

 

/s/ Mack Leath

Mack Leath

Chief Executive Officer, Chief Financial Officer and Principal Executive Officer

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the annual report of Mitesco, Inc. (the “Company”) on Form 10-Q for the three months ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Mack Leath, Chief Executive Officer, Chief Financial Officer, and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1.

The quarterly report on Form 10-Q fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: August 14, 2024

 

 

/s/ Mack Leath

Mack Leath

Chief Executive Officer, Chief Financial Officer, and Principal Executive Officer

 

 

 
v3.24.2.u1
Cover - shares
6 Months Ended
Jun. 30, 2024
Aug. 14, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Jun. 30, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Entity Information [Line Items]    
Entity Registrant Name MITESCO, INC.  
Entity Central Index Key 0000802257  
Entity File Number 000-53601  
Entity Tax Identification Number 87-0496850  
Entity Incorporation, State or Country Code NV  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 505 Beachland Blvd., Suite 1377  
Entity Address, City or Town Vero Beach  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 32963  
Entity Phone Fax Numbers [Line Items]    
City Area Code 844  
Local Phone Number 383-8689  
Entity Listings [Line Items]    
Entity Common Stock, Shares Outstanding   6,358,582
v3.24.2.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 40,196 $ 2,838
Prepaids and other current assets 6,000 0
Total current assets 46,196 2,838
Total assets 46,196 2,838
Current liabilities:    
Accounts payable and accrued liabilities 7,350,307 7,838,112
Derivative liabilities 152,945 152,945
Lease liability - operating lease, current 99,477 99,477
SBA loan payable 408,303 421,788
Other current liabilities 96,136 121,136
Legal settlements 2,452,768 2,219,886
Total current liabilities 15,184,831 14,134,595
Total liabilities 15,184,831 14,134,595
Stockholders' deficit    
Common stock, $0.01 par value, 500,000,000 shares authorized, 5,958,582 and 5,567,957 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 59,587 55,680
Additional paid-in capital 47,211,508 47,856,444
Accumulated deficit (62,412,745) (62,046,824)
Total stockholders' deficit (15,138,635) (14,131,757)
Total liabilities and stockholders' deficit 46,196 2,838
Nonrelated Party [Member]    
Current liabilities:    
Accrued interest 449,455 348,821
Notes payable, net of discounts 1,244,429 945,429
Preferred stock dividends payable 2,338,790 1,551,833
Related Party [Member]    
Current liabilities:    
Accrued interest 82,845 61,792
Notes payable, net of discounts 300,012 300,012
Preferred stock dividends payable 209,364 73,364
Series A Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 0 0
Series C Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 0 0
Series D Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 2,500 2,500
Series F Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value 201 201
Series X Preferred Stock [Member]    
Stockholders' deficit    
Preferred stock, Value $ 314 $ 242
v3.24.2.u1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
Common stock, par value (in Dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 5,958,582 5,567,957
Common stock, shares outstanding 5,958,582 5,567,957
Series A Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series D Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 250,000 250,000
Preferred stock, shares outstanding 250,000 250,000
Series F Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 20,057 20,057
Preferred stock, shares outstanding 20,057 20,057
Series X Preferred Stock [Member]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares issued 31,427 24,227
Preferred stock, shares outstanding 31,427 24,227
v3.24.2.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenue $ 6,000 $ 0 $ 6,000 $ 0
General and administrative 345,877 558,277 481,353 2,188,180
Impairment of fixed assets 0 3,535 0 132,000
Total operating expenses 345,877 561,812 481,353 2,320,180
Net loss from operations (339,877) (561,812) (475,353) (2,320,180)
OTHER INCOME (EXPENSES):        
Equity investment incentive 0 (6,429,107) 0 (6,429,107)
Gain on termination of operating lease 0 0 233,205 0
Gain on forgiveness of debt 0 25,000 0 25,000
Gain on sale of assets 0 20,097 0 20,097
Gain on issuance of shares to service provided 0 33,092 0 33,092
Loss on settlement of true-up obligations 0 (119,370) 0 (119,370)
Loss on legal settlement 0 (18,759) 0 (18,759)
(Loss) Gain on revaluation of derivative liabilities 0 39,738 0 (71,040)
Total other income (expense) (72,568) (6,608,699) 109,432 (8,139,112)
Net income (loss) from continuing operations (412,445) (7,170,511) (365,921) (10,459,292)
Net loss from discontinued operations 0 (373,759) 0 (2,698,803)
Consolidated net loss (412,445) (7,544,270) (365,921) (13,158,095)
Preferred stock dividends     (995,455) (548,363)
Net loss available to common shareholders $ (769,335) $ (8,012,815) $ (1,361,376) $ (13,706,459)
Net loss per common share - continuing operations (in Dollars per share) $ (0.15) $ (1.5) $ (0.25) $ (2.23)
Net loss per common share - discontinued operations (in Dollars per share) 0 (0.06) 0 (0.53)
Net loss per common share (in Dollars per share) $ (0.15) $ (1.55) $ (0.25) $ (2.76)
Weighted average shares outstanding (in Shares) 5,802,968 5,157,610 5,698,479 4,963,755
Nonrelated Party [Member]        
OTHER INCOME (EXPENSES):        
Interest expense $ (67,603) $ (129,436) $ (108,227) $ (1,505,502)
Preferred stock dividends (309,143) (409,420) (859,455) (471,243)
Related Party [Member]        
OTHER INCOME (EXPENSES):        
Interest expense (4,965) (29,954) (15,546) (73,523)
Preferred stock dividends $ (47,747) $ (59,125) $ (136,000) $ (77,121)
v3.24.2.u1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
Stock issued for dividends payable [Member]
Common Stock [Member]
Series X Preferred Stock [Member]
Stock issued for dividends payable [Member]
Additional Paid-in Capital [Member]
Series X Preferred Stock [Member]
Stock issued for dividends payable [Member]
Series X Preferred Stock [Member]
Series X Preferred Stock [Member]
Preferred Stock [Member]
Series X Preferred Stock [Member]
Series X Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series X Preferred Stock [Member]
Commitments [Member]
Common Stock [Member]
Commitments [Member]
Additional Paid-in Capital [Member]
Commitments [Member]
Trueup Agreement [Member]
Common Stock [Member]
Trueup Agreement [Member]
Additional Paid-in Capital [Member]
Trueup Agreement [Member]
Legal Settlement [Member]
Common Stock [Member]
Legal Settlement [Member]
Additional Paid-in Capital [Member]
Legal Settlement [Member]
Shares Previously Subscribed [Member]
Common Stock [Member]
Shares Previously Subscribed [Member]
Additional Paid-in Capital [Member]
Shares Previously Subscribed [Member]
Stock Subscribed [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Series C and Series D preferred shares [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Convertible Debt [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Accounts Payable [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Series C and Series D preferred shares [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Preferred Stock [Member]
Series X Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Series C and Series D preferred shares [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Convertible Debt [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Series F Preferred Stock [Member]
Convertible Debt [Member]
Additional Paid-in Capital [Member]
Series F Preferred Stock [Member]
Series C and Series D preferred shares [Member]
Additional Paid-in Capital [Member]
Convertible Debt [Member]
Additional Paid-in Capital [Member]
Accounts Payable [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Stock Subscribed [Member]
Series F Preferred Stock [Member]
Convertible Debt [Member]
Series F Preferred Stock [Member]
Series C and Series D preferred shares [Member]
Convertible Debt [Member]
Accounts Payable [Member]
Total
Balance at Dec. 31, 2022                                       $ 31,000         $ 242   $ 10,476   $ 46,305         $ 29,452,514 $ (48,714,461) $ 36,575         $ (19,137,349)
Balance (in Shares) at Dec. 31, 2022                                       3,100,000         24,227   1,047,619   4,630,372                        
Shares issued for conversion of note payable                                                       $ 571       $ 82,885             $ 83,456    
Shares issued for conversion of note payable (in Shares)                                                       57,138                          
Vesting of stock options issued to employees                                                                   933             933
Shares issued to service providers                                                         $ 3,000         894,000             897,000
Shares issued to service providers (in Shares)                                                         300,000                        
Shares issued for Series X dividends $ 81 $ 35,248 $ 35,329                                                                            
Shares issued for Series X dividends (in Shares) 8,063                                                                                
Preferred stock dividends                                                                   (79,818)             (79,818)
Net income (loss)                                                                     (5,613,825)           (5,613,825)
Balance at Mar. 31, 2023                                       $ 31,000         $ 242   $ 10,476   $ 49,957         30,385,762 (54,328,286) 36,575         (23,814,274)
Balance (in Shares) at Mar. 31, 2023                                       3,100,000         24,227   1,047,619   4,995,573                        
Balance at Dec. 31, 2022                                       $ 31,000         $ 242   $ 10,476   $ 46,305         29,452,514 (48,714,461) 36,575         (19,137,349)
Balance (in Shares) at Dec. 31, 2022                                       3,100,000         24,227   1,047,619   4,630,372                        
Net income (loss)                                                                                 (13,158,095)
Balance at Jun. 30, 2023                                       $ 7,500       $ 163 $ 242       $ 51,388         43,355,536 (61,872,556)           23,814,274
Balance (in Shares) at Jun. 30, 2023                                       750,000       16,353 24,227       5,138,575                        
Balance at Mar. 31, 2023                                       $ 31,000         $ 242   $ 10,476   $ 49,957         30,385,762 (54,328,286) $ 36,575         (23,814,274)
Balance (in Shares) at Mar. 31, 2023                                       3,100,000         24,227   1,047,619   4,995,573                        
Shares issued             $ 30 $ 3,778 $ 3,808 $ 947 $ 118,423 $ 119,370 $ 222 $ 18,537 $ 18,759 $ 30 $ 36,545 $ (36,575)                                              
Shares issued (in Shares)             2,952     94,738     22,174     2,926                                                  
Shares issued for conversion of note payable                                     $ (23,500)   $ 81 $ 2 $ 63     $ (10,476)       $ 8,612,993 $ 2,809,415   $ 146,212       $ 8,613,074 $ 2,775,502   $ 146,214  
Shares issued for conversion of note payable (in Shares)                                     (2,350,000)   8,116 147 6,344     (1,047,619)                              
Series A dividends previously satisfied                                                                   10,967             10,967
Series F shares sold for cash                                               $ 17                   1,655,483             1,655,500
Series F shares sold for cash (in Shares)                                               1,746                                  
Vesting of stock options issued to employees                                                                   933             933
Shares issued for Series X dividends $ 202 25,033 25,235                                                                            
Shares issued for Series X dividends (in Shares) 20,212                                                                                
Preferred stock dividends                                                                   (468,545)             (457,578)
Net income (loss)                                                                     (7,544,270)           (7,544,270)
Balance at Jun. 30, 2023                                       $ 7,500       $ 163 $ 242       $ 51,388         43,355,536 (61,872,556)           23,814,274
Balance (in Shares) at Jun. 30, 2023                                       750,000       16,353 24,227       5,138,575                        
Balance at Dec. 31, 2023                                       $ 2,500       $ 201 $ 242       $ 55,680         47,856,444 (62,046,824)           (14,131,757)
Balance (in Shares) at Dec. 31, 2023                                       250,000       20,057 24,227       5,567,957                        
Shares issued for Series X dividends $ 661 52,195 52,856                                                                            
Shares issued for Series X dividends (in Shares) 66,070                                                                                
Preferred stock dividends                                                                   (638,565)             (638,565)
Net income (loss)                                                                     46,524           46,524
Balance at Mar. 31, 2024                                       $ 2,500       $ 201 $ 242       $ 56,341         47,270,074 (62,000,300)           (14,670,942)
Balance (in Shares) at Mar. 31, 2024                                       250,000       20,057 24,227       5,634,027                        
Balance at Dec. 31, 2023                                       $ 2,500       $ 201 $ 242       $ 55,680         47,856,444 (62,046,824)           $ (14,131,757)
Balance (in Shares) at Dec. 31, 2023                                       250,000       20,057 24,227       5,567,957                        
Series F shares sold for cash (in Shares)                                                                                 300,000
Shares issued for Series X dividends (in Shares)                                                                                 90,625
Net income (loss)                                                                                 $ (365,921)
Balance at Jun. 30, 2024                                       $ 2,500       $ 201 $ 314       $ 59,587         47,211,508 (62,412,745)           (15,138,635)
Balance (in Shares) at Jun. 30, 2024                                       250,000       20,057 31,427       5,958,582                        
Balance at Mar. 31, 2024                                       $ 2,500       $ 201 $ 242       $ 56,341         47,270,074 (62,000,300)           (14,670,942)
Balance (in Shares) at Mar. 31, 2024                                       250,000       20,057 24,227       5,634,027                        
Shares issued for Series X dividends $ 246 $ 19,396 $ 19,642                                                                            
Shares issued for Series X dividends (in Shares) 24,555                                                                                
Shares issued as compensation       $ 72 $ 179,928 $ 179,928                                             $ 3,000         99,000             102,000
Shares issued as compensation (in Shares)       7,200                                                 300,000                        
Preferred stock dividends                                                                   (356,890)             (356,890)
Net income (loss)                                                                     (412,445)           (412,445)
Balance at Jun. 30, 2024                                       $ 2,500       $ 201 $ 314       $ 59,587         $ 47,211,508 $ (62,412,745)           $ (15,138,635)
Balance (in Shares) at Jun. 30, 2024                                       250,000       20,057 31,427       5,958,582                        
v3.24.2.u1
CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Net income loss from continuing operations $ (365,921) $ (10,459,292)
Adjustments to reconcile net loss to net cash used in operating activities:    
Impairment of right of use asset 0 132,000
Depreciation expense 0 11,393
Penalties on notes payable 0 1,102,778
Equity investment incentive   6,501,107
Share based compensation 282,000 898,866
Shares issued as compensation for fundraising 0 3,808
Shares issued for true-up liability 0 119,370
Gain on forgiveness of note payable 0 25,000
Gain (loss) on lease terminations (233,205) 0
Gain (loss) on revaluation of derivative liabilities 0 71,040
Loss on legal settlement 0 18,759
Changes in operating assets and liabilities:    
Accounts receivable (6,000) 0
Prepaid expenses 0 51,632
Accounts payable and accrued liabilities (46,718) 757,397
Other current liabilities 0 25,000
Net cash used in operating activities from continuing operations (248,157) (424,068)
Net cash provided by operating activities from discontinued operations 0 (94,164)
Net cash used in operating activities (248,157) (518,232)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Principal payments on SBA Loan (13,485) 0
Proceeds from notes payable, net of discounts 299,000 0
Proceeds from sale of Series F Preferred stock, net of fees 0 738,500
Net cash provided by financing activities from continuing operations 285,515 738,500
Net cash provided by financing activities from discontinued operations 0 0
Net cash provided by financing activities 285,515 738,500
Net change in cash 37,358 220,268
Cash at beginning of period 2,838 35,623
Cash at end of period 40,196 255,891
Supplemental disclosure of cash flow information:    
Cash paid for interest 0 0
Cash paid for taxes 0 0
Supplemental disclosure of financing cash flow information:    
Preferred stock dividends 995,455 548,363
Shares issued for Series X dividends 72,498 60,564
Increase in capital expenditures included in accounts payable 0 110,511
Nonrelated Party [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of discount on notes payable 0 32,011
Changes in operating assets and liabilities:    
Accrued interest 100,634 257,650
Supplemental disclosure of financing cash flow information:    
Preferred stock dividends 859,455 471,243
Related Party [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of discount on notes payable 0 19,617
Changes in operating assets and liabilities:    
Accrued interest 21,053 57,796
Supplemental disclosure of financing cash flow information:    
Preferred stock dividends 136,000 77,121
Accounts Payable [Member]    
Supplemental disclosure of financing cash flow information:    
Conversion of payable to Series F preferred stock 0 146,214
Series C and Series D preferred shares [Member]    
Supplemental disclosure of financing cash flow information:    
Conversion of Series C and Series D preferred stock to Series F preferred stock 0 420,681
Series F Preferred Stock [Member]    
Supplemental disclosure of financing cash flow information:    
Preferred stock dividends 941,713  
Conversion of payable to Series F preferred stock 0 8,111,253
Stock Subscribed [Member]    
Supplemental disclosure of financing cash flow information:    
Stock Issued for common stock subscribed $ 0 $ 82,885
v3.24.2.u1
Description of Business
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1: Description of Business

 

Company Overview

 

Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company completed a move of its corporate status to Nevada from Delaware in order to effect reduced costs.

 

The details can be found at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518523001074/mitesco20231016_8k.htm .

 

From 2020 through 2022, our operations were focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability.

 

We are a holding company seeking to provide products, services and technology. We have a number of near-term opportunities that we hope to pursue, assuming the capital markets make sufficient funding available at reasonable rates. During the first quarter of 2024 we recruited a number of individuals to a newly formed Advisory Board, who might assist the Company in determining the viability of certain ventures going forward. These individuals have a background in data center services, cyber and data security and software applications related to infrastructure design, implementation and management including geographical information systems (GIS).

 

In June 2024 we announced the formation of two (2) new wholly owned business units, Centcore, LLC, who is providing data center services including cloud computing and application hosting, and Vero Technology Ventures, LLC, whose aim is to seek investment and acquisition opportunities, generally in the areas of cloud computing and data center related applications.

 

Centcore has two (2) areas of focus. The first, generic data center services, is aimed at hosting applications for a specific user, sometimes referred to as “managed services offerings” or MSO, where the client moves the software licensed from various vendors, or internally developed, into our data center where we maintain the computing, communications and backup environment. The second focus involves hosting application software developed by software vendors, from which they will sell the use of the software by their end user clients on a “cloud” basis. By taking this approach we gain the business of the vendor, and their clients, perhaps allowing us to grow at a faster rate with lower cost of sales. We have developed the “Centcore Partner Program” where we will help promote the software vendors who are hosting in our data centers. If we are successful helping the vendor grow his business, we will have provided a “value added service”, and benefit from increased utilization of our computing resources by not only the vendor, but also his new end user clients. Our initial focus for this area is on software providers who serve the “infrastructure” market doing design, engineering, construction and maintenance of significant assets. We desire to create “life cycle” relationships with both the design teams, and owners which may include private owners such as manufacturers and utilities, or publicly owned assets for municipalities, states or federal governments, domestically and internationally.

 

We have retained proven professionals in the data center, cyber security and infrastructure services areas to support our needs on a per hour basis, which we believe will allow us to control our costs relative to business activity, without significant staffing internally.

v3.24.2.u1
Going Concern
6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]

Note 2: Going Concern

 

As of June 30, 2024, the Company had cash and cash equivalents of approximately $40,000, current liabilities of approximately $15.2 million, and has incurred significant losses from the previous clinic operations. As previously noted, we made a strategic decision to reduce our capital needs by closing our entire clinic operations in the fourth quarter of 2022 and releasing our entire staff, due to lack of profitability. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan.

 

As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists.

 

The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

v3.24.2.u1
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]

Note 3: Summary of Significant Accounting Policies

 

Basis of Presentation – The consolidated financial statements are prepared in conformity with accounting principles accepted in the United States of America (“GAAP”).

 

The consolidated financial statements and related disclosures as of June 30, 2024, are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. In our opinion, these unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited financial statements should be read in conjunction with the audited financial statements of the Company for the years ended December 31, 2023, and 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024. The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year ended December 31, 2024.

 

Principles of Consolidation The accompanying consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC, The Good Clinic, LLC, Vero Technology Ventures, LLC, and Centcore, LLC. In addition, we relied on the operating activities of certain legal entities in which we did not maintain a controlling ownership interest, but over which we had indirect influence and of which we were considered the primary beneficiary. These entities are typically subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

 

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options, and convertible instruments. For the three and six months ended June 30, 2024, the effect of 673,208 warrants to purchase shares of common stock, 13,667 options to purchase shares of common stock, and 1,216,616 shares of common stock issuable upon conversion of Series D preferred stock were excluded from the calculation of net loss per share as their effect was antidilutive. For the three and six months ended June 30, 2023 the effect of 673,208 warrants to purchase shares of common stock, 209,381 options to purchase shares of common stock, and 3,467,464 shares of common stock issuable upon conversion of Series D preferred stock were excluded from the calculation of net loss per share as their effect was antidilutive.

 

Discontinued Operations - The accompanying financial statements are prepared with the guidance of ASU 2014-08, “Reporting Discontinued Operations”, and ASC Topic 205, Presentation of Financial Statements, and ASC Topic 360, Property, Plant and Equipment.

 

Recent Accounting Standards – In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

 

There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

v3.24.2.u1
Discontinued Operations
6 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

Note 4: Discontinued Operations

 

In the fourth quarter of fiscal 2022, we made the strategic decision to close the entire clinic operation and release our staff due to a lack of profitability. On December 8, 2023, the Company sold the remaining assets of The Good Clinic, LLC to Leading Primary Care LLC, a company organized by Michael C. Howe, the former CEO of The Good Clinic, LLC for total consideration of approximately $2.5 million. ASC 360-10-45-9 requires that a long-lived asset (disposal group) to be sold shall be classified as held for sale in the period in which a set of criteria have been met, including criteria that the sale of the asset (disposal group) is probable and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. This criterion was achieved on December 8, 2023. Additionally, the discontinued operations are comprised of the entirety of The Good Clinic, LLC. For comparability purposes certain prior period line items relating to the assets held for sale have been reclassified and presented as discontinued operations for all periods presented in the accompanying consolidated statements of net loss and comprehensive loss and the consolidated balance sheets.

 

The Company had no assets or liabilities classified that were classified as held as part of discontinued operations as of June 30, 2024, or December 31, 2023.

 

The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations:

 

   

Three Months Ended

   

Six Months Ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Revenue

  $ -     $ -     $ -     $ -  

Cost of goods sold

    -       5,601       -       8,020  

Gross margin

            (5,601 )     -       (8,020 )
                                 

Selling, general, and administrative expenses

    -       (216,404 )     -       (597,905 )

Impairment of assets

    -       (68,034 )     -       (2,211,462 )
                                 

Other (income) expense:

                               

Gain on termination of operating lease

    -       -       -       287,897  

Interest expense

    -       (83,720 )     -       (169,313 )

Loss from discontinued operations, net of tax

  $ -     $ (373,759 )   $ -     $ (2,698,803 )

 

The following information presents the major classes of line items constituting significant operating and investing cash flow activities in the consolidated statements of cash flows relating to discontinued operations:

 

   

Six Months Ended

 
   

June 30,

   

June 30,

 
   

2024

   

2023

 
                 

Depreciation expense

  $ -     $ 81,764  

Impairment of property and equipment

  $ -     $ 2,211,462  

Changes in accounts payable and accrued liabilities

  $ -     $ 444,884  
v3.24.2.u1
Accounts Payable and Accrued Liabilities
6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 5: Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consisted of the following at June 30, 2024, and December 31, 2023:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Trade accounts payable

  $ 6,516,812     $ 7,094,334  

Accrued payroll and payroll taxes

    833,495       743,778  

Total accounts payable and accrued liabilities

  $ 7,350,307     $ 7,838,112  
v3.24.2.u1
Right to Use Assets and Lease Liabilities – Operating Leases
6 Months Ended
Jun. 30, 2024
Disclosure Text Block [Abstract]  
Lessee, Operating Leases [Text Block]

Note 6: Right to Use Assets and Lease Liabilities Operating Leases

 

The Company had operating leases for its clinics for which the Company is currently in negotiations with the Lessors to settle the remaining amounts owed after closing the clinic facilities. The Company’s lease expense was entirely comprised of operating leases and is reported as a component of discontinued operations as a result of closing of the clinics and the subsequent sale of the assets. As of December 31, 2023, the Company had impaired all balances of the related right to use assets.

 

Operating lease liabilities are summarized below:

 

   

June 30 30,

2024

   

December 31,

2023

 

Lease liability

  $ 99,477     $ 99,477  

Less: current portion

    (99,477 )     (99,477 )

Lease liability, non-current

  $ -     $ -  

 

As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2023, or the six months ending June 30, 2024. As of June 30, 2024, the Company has either settled amounts owed or entered into default judgements for all leases except for the office lease, which we believe is nominal. For all leases for which a legal settlement has been entered into, all amounts have been reclassified to legal settlements as of June 30, 2024, and December 31, 2023.

 

For the period ended December 31, 2024

  $ 99,477  

For the period ended December 31, 2025

    -  

For the period ended December 31, 2026

    -  

For the period ended December 31, 2027

    -  

For the period ended December 31, 2028

    -  

Thereafter

    -  

Total

  $ 99,477  

Less: Present value discount

    -  

Lease liability

  $ 99,477  

 

As of December 31, 2023, the Company has entered into settlement agreements for certain of our leases in the amount of $2,219,886 which is recorded as Legal Settlements in the accompanying balance sheet. During the six months ended June 30, 2024, the Company recorded a gain of $233,205 as a result of a final settlement in addition to reclassifying certain accounts payable related to the leases to legal settlements. As of June 30, 2024, the Company has total legal settlement agreements in the amount of $2,452,768 which is recorded as Legal Settlements in the accompanying balance sheet.

v3.24.2.u1
SBA Loan Payable
6 Months Ended
Jun. 30, 2024
Small Business Administration Loan Payable Abstract  
Small Business Administration Loan Payable [Text Block]

Note 7: SBA Loan Payable

 

PPP Loan Conversion to SBA Loan

 

During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration (the “SBA”). On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year.

 

On July 12, 2023, the Company received confirmation of a payment plan arrangement from the SBA. Pursuant to this payment plan, the Company agreed to pay a minimum of $2,595 each month until the loan is paid in full in July 2028. The SBA confirmed the balance due on the loan, including principal and interest, was $467,117. The Company will amortize the balance due on the loan including interest at the original PPP loan rate of 1% per annum; a gain on restructure of debt in the amount of $40,622 was recorded on this transaction during the year ended December 31, 2023, and the balance of the loan was recorded at the amount of $433,343 representing the net cash flows discounted at 1%. During the six months ended June 30, 2024, the Company made principal payments of $13,485 on this loan and recorded interest in the amount of $2,087.

v3.24.2.u1
Notes Payable
6 Months Ended
Jun. 30, 2024
Notes Payable [Line Items]  
Debt Disclosure [Text Block]

Note 8: Notes Payable

 

The following table summarizes the outstanding notes payable as of June 30, 2024, and December 31, 2023, respectively:

 

   

June 30, 2024

   

December 31, 2023

 

Kishon Note

  $ 431,666     $ 431,666  

Finnegan Note 1

    51,765       51,765  

Finnegan Note 2

    32,353       32,353  

Schrier Note

    25,882       25,882  

Nommsen Note

    64,705       64,705  

Caplan Note

    64,705       64,705  

Finnegan Note 3

    32,353       32,353  

Lightmas Note

    66,000       66,000  

Lewis Note

    33,000       33,000  

Goff Note

    33,000       33,000  

Hagan Note

    110,000       110,000  

Cavalry Note 1

    25,000       -  

Cavalry Note 2

    50,000       -  

Mercer Note 1

    25,000       -  

Mercer Note 2

    50,000       -  

ABJ Note

    50,000       -  

Cavalry Note 3

    33,000       -  

Mercer Note 3

    33,000       -  

ABJ Note 2

    33,000       -  

Notes Payable

    1,244,429       945,429  
                 

Current Portion

    1,244,429       945,429  

Long-term portion

  $ -     $ -  

 

Kishon Note

 

On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793.

 

The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022, and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492.

 

During the year ended December 31, 2023, a default penalty in the amount of $138,889 and an additional fee in the amount of $15,000 were added to the principal amount of the Kishon Note. At December 31, 2023, principal and interest in the amount of $431,666 and $88,909, respectively, were due on the Kishon Note. At June 30, 2024, principal and interest in the amount of $431,666 and $127,653, respectively, were due on the Kishon Note. This note was in default at June 30, 2024.

 

Finnegan Note 1

 

On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1.

 

Principal and accrued interest in the amount of $51,765 and $11,889, respectively, were due on this note at December 31, 2023. At June 30, 2024, principal and interest in the amount of $51,765 and $16,142, respectively, were due on the Kishon Note. This note was in default at June 30, 2024.

 

Finnegan Note 2

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2.

 

At December 31, 2023principal and accrued interest in the amount of $32,353 and $7,341, respectively, were due on this note. At June 30, 2024, principal and interest in the amount of $32,353 and $9,999, respectively, were due on the Kishon Note. This note was in default at June 30, 2024.

 

Schrier Note

 

On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note.

 

At December 31, 2023, principal and accrued interest in the amount of $25,882 and $5,383, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $25,882 and $7,510, respectively, were due on this note. This note was in default at June 30, 2024.

 

Nommsen Note

 

On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $13,685, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $64,705 and $19,001, respectively, were due on this note. This note was in default at June 30, 2024.

 

Caplan Note

 

On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,705 and $12,989, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $64,705 and $18,305, respectively, were due on this note This note was in default at June 30, 2024.

 

Finnegan Note 3

 

On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3.

 

At December 31, 2023, principal and accrued interest in the amount of $32,353 and $6,350, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $32,353 and $9,008, respectively, were due on this note. This note was in default at June 30, 2024.

 

Lightmas Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $60,000 to Frank Lightmas (the “Lightmas Note”). The Lightmas Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lightmas Note was $51,000; the amount payable at maturity will be $60,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lightmas Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lightmas Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lightmas Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Lightmas reasonably believes contains a term that is more favorable than those in the Lightmas Note, the Company shall notify Mr. Lightmas of such term, and such term, at the option of Mr. Lightmas, shall become a part of the Lightmas Note. In addition, Mr. Lightmas received 492 shares of common stock with a value of $2,640; this amount was recorded as a discount to the Lightmas Note.

 

At December 31, 2023, principal and accrued interest in the amount of $66,000 and $13,325, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $66,000 and $18,748, respectively, were due on this note. This note was in default at June 30, 2024.

 

Lewis Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Lisa Lewis (the “Lewis Note”). The Lewis Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lewis Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lewis Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lewis Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Lewis Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lewis reasonably believes contains a term that is more favorable than those in the Lewis Note, the Company shall notify Ms. Lewis of such term, and such term, at the option of Ms. Lewis, shall become a part of the Lewis Note. In addition, Ms. Lewis received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Lewis Note.

 

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $33,000 and $9,374, respectively, were due on this note. This note was in default at June 30, 2024.

 

Goff Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $30,000 to Sharon Goff (the “Goff Note”). The Goff Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Goff Note was $25,500; the amount payable at maturity will be $30,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Goff Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Goff Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Goff Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Goff reasonably believes contains a term that is more favorable than those in the Goff Note, the Company shall notify Ms. Goff of such term, and such term, at the option of Ms. Goff, shall become a part of the Goff Note. In addition, Ms. Goff received 246 shares of common stock with a value of $1,320; this amount was recorded as a discount to the Goff Note.

 

At December 31, 2023, principal and accrued interest in the amount of $33,000 and $6,663, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $33,000 and $9,374, respectively, were due on this note. This note was in default at June 30, 2024.

 

Hagan Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $100,000 to Cliff Hagan (the “Hagan Note”). The Hagan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Hagan Note was $85,000; the amount payable at maturity will be $100,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Hagan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Hagan Note entered default status on December 11, 2022, and the interest rate increased to 18%. The Hagan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Hagan reasonably believes contains a term that is more favorable than those in the Hagan Note, the Company shall notify Mr. Hagan of such term, and such term, at the option of Mr. Hagan, shall become a part of the Hagan Note. In addition, Mr. Hagan received 820 shares of common stock with a value of $4,715; this amount was recorded as a discount to the Hagan Note.

 

At December 31, 2023, principal and accrued interest in the amount of $110,000 and $21,793, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $110,000 and $30,831, respectively, were due on this note. This note was in default at June 30, 2024.

 

Cavalry 2024 Note 1

 

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Cavalry Fund LLP (“Cavalry”), (the “Cavalry Note 1”) with a due date of January 23, 2025. The Cavalry Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $25,000 and $1,587, respectively, were due on this note.

 

Cavalry 2024 Note 2

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Cavalry, (the “Cavalry Note 2”) with a due date of February 28, 2025. The Cavalry Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $2,688, respectively, were due on this note.

 

Cavalry 2024 Note 3

 

On May 13, 2024, the Company issued a 10% Promissory Note in the principal amount of $33,000 to Cavalry, (the “Cavalry Note 3”) with a due date of May 13, 2025. The Cavalry Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $434, respectively, were due on this note.

 

Mercer 2024 Note 1

 

On January 23, 2024, the Company issued a 10% Promissory Note in the principal amount of $25,000 to the Mercer Street Global Opportunity Fund (“Mercer”), (the “Mercer Note 1”) with a due date of January 23, 2025. The Mercer Note bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Cavalry Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $25,000 and $1,587, respectively, were due on this note.

 

Mercer 2024 Note 2

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mercer, (the “Mercer Note 2”) with a due date of February 28, 2025. The Mercer Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $2,675, respectively, were due on this note.

 

Mercer 2024 Note 3

 

On May 13, 2024, the Company issued a 10% Promissory Note in the principal amount of $33,000 to Mercer, (the “Mercer Note 3”) with a due date of May 13, 2025. The Mercer Note 3 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the Mercer Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $416, respectively, were due on this note.

 

AJB 2024 Note 1

 

On February 28, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB Capital Investments, LLC (“AJB”), (the “AJB Note 1”) with a due date of February 28, 2025. The AJB Note 1 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $2,605, respectively, were due on this note.

 

AJB 2024 Note 2

 

On May 15, 2024, the Company issued a 10% Promissory Note in the principal amount of $50,000 to AJB, (the “AJB Note 2”) with a due date of May 15, 2025. The AJB Note 2 bears interest at the rate of 10% per annum which will accrue monthly. Following an event of default as defined in the AJB Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 12%.

 

At June 30, 2024, principal and accrued interest in the amount of $50,000 and $416, respectively, were due on this note.

 

Aggregate interest expense on the above notes payable was $108,227 for the six months ended June 30, 2024. Accrued interest on notes payable was $449,455 and $348,821 at June 30, 2024, and December 31, 2023, respectively.

Related Party [Member]  
Notes Payable [Line Items]  
Debt Disclosure [Text Block]

Note 9: Notes Payable Related Parties

 

The following table summarizes the outstanding related party notes payable as of June 30, 2024, and December 31, 2023, respectively.

 

   

June 30,

2024

   

December 31,

2023

 

M Diamond Note

    64,706       64,706  

Dobbertin Note

    19,412       19,412  

Lindstrom Note

    45,294       45,294  

Mitchell Note

    78,100       78,100  

Leath Note

    55,000       55,000  

November 29, 2022, Notes

    37,500       37,500  

Notes Payable

    300,012       300,012  
                 

Current Portion, net of discount

  $ 300,012     $ 300,012  

Long-term portion, net of discount

    -       -  

 

M Diamond Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). Ms. Diamond is the daughter of Larry Diamond, former CEO. The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note.

 

At December 31, 2023, principal and accrued interest in the amount of $64,706 and $14,682, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $64,706 and $17,636, respectively, were due on this note. This note was in default at June 30, 2024.

 

Dobbertin Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, who was the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note.

 

At December 31, 2023, principal and accrued interest in the amount of $19,412 and $4,405, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $19,412 and $5,989, respectively, were due on this note. This note was in default at June 30, 2024.

 

Lindstrom Note

 

On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, who was the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1.

 

At December 31, 2023, principal and accrued interest in the amount of $45,294 and $10,277, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $45,294 and $13,973, respectively, were due on this note. This note was in default at June 30, 2024.

 

Mitchell Note

 

On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Mitchell Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Mitchell reasonably believes contains a term that is more favorable than those in the Mitchell Note, the Company shall notify Mr. Mitchell of such term, and such term, at the option of Mr. Mitchell, shall become a part of the Mitchell Note. In addition, Mr. Mitchell received 582 shares of common stock with a value of $3,124; this amount was recorded as a discount to the Mitchell Note.

 

At December 31, 2023, principal and accrued interest in the amount of $78,100 and $15,768, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $78,100 and $22,185, respectively, were due on this note. This note was in default at June 30, 2024.

 

Leath Note

 

On September 15, 2022, the Company issued a 10% Promissory Note in the principal amount of $50,000 to Mack Leath (the “Leath Note”). The Leath Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 15, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Leath Note was $42,500; the amount payable at maturity will be $50,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Leath Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Leath Note entered default status on December 16, 2022, and the interest rate increased to 18%. The Leath Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Leath reasonably believes contains a term that is more favorable than those in the Leath Note, the Company shall notify Mr. Leath of such term, and such term, at the option of Mr. Leath, shall become a part of the Leath Note. In addition, Mr. Leath received 410 shares of common stock with a value of $2,868; this amount was recorded as a discount to the Leath Note.

 

At December 31, 2023, principal and accrued interest in the amount of $55,000 and $10,757, respectively, were due on this note. At June 30, 2024, principal and accrued interest in the amount of $55,000 and $15,276, respectively, were due on this note. This note was in default at June 30, 2024.

 

November 29, 2022, Notes

 

On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, who was the Company’s CFO and Board Member; (2) Lawrence Diamond, who was the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, who was a Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, who was a Board Member; (6) Jenny Lindstrom, who was the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, who was the Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”).

 

The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 13. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022, because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022.

 

Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022.

 

During the year ended December 31, 2023, interest in the amount of $11,967 was accrued on the November 29 Notes.

 

On September 29, 2023, three of the November 29 Lenders (1) Thomas Brodmerkel, (2) Lawrence Diamond, and (3) Faraz Naqvi converted their November 29 Notes into shares of the Company’s Series F Preferred Stock as follows: Each of the noteholders converted an equity investment incentive in the amount of $13,553 representing 65% of the total amount due under the November 29 Note , along with original principal of $18,750 and accrued interest of $2,101 (a total of $34,404) into 34 shares of the Company’s Series F Preferred Stock. Other than the equity investment incentives of $13,553, there was no gain or loss recognized on this transaction as the Series F Preferred Stock was issued at its face value of $1,000 per share.

 

On September 29, 2023, one of the November 29 Lenders, Sheila Schweitzer, converted her November 29 Note into shares of the Company’s restricted common stock as follows: principal of $18,750 and accrued interest of $2,101 were converted at a price of $0.80 per share into 26,064 shares of the Company’s common stock.

 

On December 8, 2023, pursuant to the Howe debt exchange agreement, Mr. Howe exchanged his note in the principal amount of $18,750 and accrued interest of $2,682 for certain assets of the company. No amounts were due under the Howe note as of December 31, 2023.

 

At December 31, 2023, there was principal and interest in the aggregate amount of $37,500 and $5,903, respectively, due on the two November 29 Notes that are still outstanding. At June 30, 2024, there was principal and interest in the aggregate amount of $37,500 and $7,785, respectively, due on the two November 29 Notes that are still outstanding.

 

Aggregate interest expense as described on the above notes payable – related parties was $15,546 for the six months ended June 30, 2024. Accrued interest on notes payable – related parties were $82,845 and $61,792 at June 30, 2024, and December 31, 2023, respectively.

v3.24.2.u1
Derivative Liabilities
6 Months Ended
Jun. 30, 2024
Disclosure Text Block [Abstract]  
Derivatives and Fair Value [Text Block]

Note 10: Derivative Liabilities

 

Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructuring, and at each period end.

 

Derivative liability activity for the six months ended June 30, 2024, is summarized in the table below:

 

December 31, 2023

  $ 152,945  

True-up features issued

    -  

Settled upon conversion or exercise

    -  

Loss on revaluation

    -  

June 30, 2024

  $ 152,945  

 

The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations:

 

   

June 30,

   

December 31,

 
   

2024

   

2023

 

Volatility

    475.7 %     475.7 %

Stock Price

  $ 0.0250     $ 0.0250  

Risk-free interest rates

    5.21 %     5.21 %

Term (years)

    0.39       0.39  

 

Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation:

 

 

The stock price would fluctuate with the Company projected volatility.

 

The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation.

 

The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1.

 

In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions.

 

Discount rates were based on risk-free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

v3.24.2.u1
Stockholders' Equity (Deficit)
6 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
Equity [Text Block]

Note 11: Stockholders Equity (Deficit)

 

Common Stock

 

The Company has authorized 500,000,000 shares of common stock, par value $0.01; 5,958,582 were issued and outstanding at June 30, 2024.

 

During the six months ended June 30, 2024, the Company issued 90,625 shares of common stock for dividends payable on its Series X Preferred Stock as discussed in further detail below. The price per share used in determining the number of shares issued was $.80, and not the lower price that is called for in the certificate of designation.

 

During the six months ended June 30, 2024, the Company issued 300,000 shares of common stock in aggregate to its advisory board consisting of four (4) individuals, with 75,000 shares issued to each. The Company recorded a compensation expense of $102,500 based on the closing stock price on the date of issuance.

 

Preferred Stock

 

We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, 140,000 shares of Series F Preferred, and 31,427 shares as Series X Preferred Stock.

 

Series A Preferred Stock

 

The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at June 30, 2024.

 

Series C Preferred Stock

 

The Series C Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series C ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder. The Company had no shares of Series C Preferred Stock outstanding at June 30, 2024.

 

Series D Preferred Stock

 

The Series D Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of 100% of the stated value plus accrued but unpaid dividends, accrued dividends at the rate of 6% on $1.05 per share, and converts into common shares at a rate of $0.25 per share. The Series D ranks senior to all other preferred stock of the Company except in relation to the Series X Cumulative Redeemable Perpetual Preferred Stock, which ranks Pari passu to the Series C Preferred Stock. Each holder of our Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder. The Company had 250,000 shares of Series D Preferred Stock outstanding at June 30, 2024.

 

The Company accrued dividends in the amount of $7,855 on the Series D Preferred Stock for the six months ended June 30, 2024. As of June 30, 2024, the Company had $41,654 in accrued dividends on the Series D Preferred Stock.

 

Series E Preferred Stock

 

On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are no shares of Series E Preferred Stock outstanding at June 30, 2024. No shares of Series E Preferred Stock have ever been issued.

 

As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E.

 

Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon.

 

Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120th day following the qualified offering, the Conversion Price shall be adjusted to the lesser of (a) the average VWAP per share of the Common Stock for the five (5) trading days immediately following the 120th day following the qualified offering and (b) the Conversion Price on such date, which shall in no event be less than $0.05.

 

Series F Preferred Stock

 

On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK $0.01 par value Convertible Perpetual Preferred Stock with the Delaware Secretary of State. The number of shares of Series F Preferred Stock designated is 140,000 and each share of Series F Preferred Stock has a liquidation preference of $1,000. The Series F Preferred Stock will rank senior to the Corporation’s Common Stock and on parity with all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank on parity with the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Corporation; and (iii) junior to all Preferred Stock of the Corporation with terms specifically providing that such Preferred Stock rank senior to the Series F Preferred Stock with respect to rights to the distribution of assets upon any liquidation, dissolution or winding up of the Company.

 

Holders of shares of the Series F Preferred Stock are entitled to receive payment-in-kind dividends payable only in additional shares of Series F Preferred Stock (“PIK Dividends”) at rate of 12% per annum.

 

The Series F Preferred Stock will be convertible into common stock of the Company upon the listing of the Company’s stock on any of the following trading markets: the NYSE, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, or the Nasdaq Global Select Market. The conversion price will be calculated as 65% of the volume-weighted average price of the Company’s common stock on the conversion date. The number of shares issuable upon conversion will be calculated as the liquidation preference of the Series F Preferred stock plus any accrued but unpaid dividends divided by the conversion price.

 

There are 20,057 shares of Series F Preferred Stock outstanding at June 30, 2024

 

On May 17, 2024, the holders of approximately 54.90% of the Series F Preferred shares, having met in person on May 8, 2024, have granted consent to the following modification to the terms of the Series F Preferred, effective May 15, 2024 all dividends, and any obligation to pay dividends shall cease. Any dividends accrued until May 15, 2024, shall be issued as noted in the original certificate of designation.

 

The Company accrued dividends in the amount of $941,713 on the Series F Preferred Stock for the six months ended June 30, 2024. As of June 30, 2024, the Company had $2,497,786 in accrued dividends on the Series F Preferred Stock.

 

Series X Preferred Stock

 

The Company has 31,427 and 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of June 30, 2024 and December 31, 2023. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Beginning in July 2023 the Company elected to use a price per share of $.80, a 20% discount to the average price of its common stock of $1.00, before the trading of its common stock was moved to the OTC Expert Market system. This policy has continued through June 30, 2024. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.

 

During the six months ended June 30, 2024, the Company issued 7,200 shares of Series X Preferred Stock to the officers and directors of the compensation in lieu of services in the amount of $180,000 in aggregate, or $60,000 for each of the three (3) directors.

 

On February 9, 2024, the Company issued 41,057 shares of common stock for dividends payable on its Series X Preferred Stock for the period from July 2023 through December 31, 2023, using the $.80 price per share as noted above.

 

On March 20, 2024, the Company issued a total of 25,013 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the first quarter of 2024 using the $.80 price per share as noted above.

 

On June 27, 2024, the Company issued a total of 24,555 shares of restricted common stock for the payment of dividends due for its Series X Preferred stock during the second quarter of 2024 using the $.80 price per share as noted above.

 

The Company accrued dividends in the amount of $45,886 on the Series X Preferred Stock for the six months ended June 30, 2024. As of June 30, 2024, the Company had $0 in accrued dividends on the Series X Preferred Stock.

 

Stock Options

 

On January 21, 2021, the Company filed a Form S-8 containing the Mitesco Omnibus Securities and Incentive Plan (“the Plan”) with the SEC. In Sections 4.2 and 4.3 of the Plan it is noted that the Board of Directors has the authority for the administration of the Plan. On January 7, 2024, the Board of Directors voted to a) cancel, revoke and terminate any previously issued options that have not already been exercised. For a number of technical reasons, the Plan is no longer valid, and in addition to cancellation of any outstanding options, the Board has voted to formally terminate the Plan.

 

A copy of the Form S-8 which references the Plan can be found at: https://www.sec.gov/Archives/edgar/data/802257/000118518521000098/ex_221520.htm

 

The following table summarizes the options outstanding at June 30, 2024, and the related prices for the options to purchase shares of the Company’s common stock:

 

                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

options

   

contractual

   

outstanding

   

options

   

exercisable

 

prices

   

outstanding

   

life (years)

   

options

   

exercisable

   

options

 
$ 1.50       13,667       5.79     $ 1.50       13,667     $ 1.50  
          13,667       5.79     $ 1.50       13,667     $ 1.50  

 

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 

Outstanding at December 31, 2023

    100,934     $ 10.01  

Granted

    -       -  

Cancelled/Expired

    (87,267 )   $ 11.38  

Exercised

    -       -  

Outstanding at June 30, 2024

    13,667     $ 1.50  

Options vested and exercisable

    13,667     $ 1.50  

 

At June 30, 2024, the total stock-based compensation cost related to unvested awards not yet recognized was $0. At June 30, 2024, there was no intrinsic value on the issued or vested options.

 

Warrants

 

The following table summarizes the warrants outstanding on June 30, 2024, and the related prices for the warrants to purchase shares of the Company’s common stock:

 

                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

warrants

   

contractual

   

outstanding

   

warrants

   

exercisable

 

prices

   

outstanding

   

life (years)

   

warrants

   

exercisable

   

warrants

 
$ 2.50       874       3.81     $ 2.5       874     $ 2.5  
  25.00       366,784       2.23       25.00       366,784       25.00  
  37.50       305,550       2.11       37.50       305,550       37.50  
          673,208       2.17     $ 30.64       673,208     $ 30.64  

 

The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:

 

   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding at December 31, 2023

    673,208     $ 30.64  

Granted

    -     $ -  

Exercised

    -     $ -  

Outstanding at June 30, 2024

    673,208     $ 30.64  

 

At June 30, 2024, there was no intrinsic value on the issued or vested options.

v3.24.2.u1
Fair Value of Financial Instruments
6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]

Note 12: Fair Value of Financial Instruments

 

The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at June 30, 2024, and December 31, 2023.

 

   

June 30, 2024

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  

 

   

December 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  
v3.24.2.u1
Commitments and Contingencies
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]

Note 13: Commitments and Contingencies

 

Legal

 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business.

 

On June 23, 2022, The Good Clinic LLC was notified that a former employee had filed a lawsuit for wrongful termination. The Good Clinic believes the lawsuit is without merit. Mitesco (Company) was not named in the suit. We have settled this matter as of January 11, 2024, for total consideration consisting of a cash payment of $3,000.

 

On October 25, 2022, the Company was notified that a vendor filed a lawsuit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor.

 

The Company has a number of legal situations involved with the winding down of its clinic’s business activities. These include claims regarding certain construction contracts and cancellation of leases as noted below:

 

Nordhaus Clinic

 

On November 1, 2020, we entered into an agreement to open a clinic in Minneapolis, Minnesota. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $511,000. On November 6, 2023, the Company received a termination notice from the landlord indicating the lease had been terminated. No additional claims have been received by the landlord and the Company believes no additional amounts are owed.

 

Egan Clinic a.k.a. Vikings

 

On October 14, 2021, we entered into an agreement to open a clinic in Eagan, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 96 months. Fixed rent payments under the initial term are approximately $767,000. A Summary Judgment was granted on December 4, 2023, in the amount of $488,491, and the entry of final judgment was entered on December 15, 2023, and the Company has released the property back to the leaseholder.

 

St. Paul Clinic a.k.a. The Grove

 

On August 31, 2021, we entered into an agreement to open a clinic in St. Paul, Minnesota, which began operations in the fourth quarter of 2021. The initial lease term is for 114 months. Fixed rent payments under the initial term are approximately $1,153,000. A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees. Final entry of judgment by the Court was entered against the Company on January 19, 2024, and the Company has released the property back to the leaseholder.

 

St. Louis Park Clinic a.k.a. Excelsior & Grand

 

On May 24, 2021, we entered into an agreement to open a clinic in St. Louis Park, Minnesota, which began operations in the third quarter of 2021. The initial lease term is seven years. Fixed rent payments under the initial term are approximately $673,000. The Company agreed to and executed a Confession of Judgment in the amount of $425,351 on April 2, 2024, and has released the property back to the leaseholder. We received the fully executed and recorded judgement on April 10, 2024.

 

Eden Prairie Clinic a.k.a. TP Elevate

 

On June 8, 2021, we entered into an agreement to open a clinic in Eden Prairie, Minnesota, which began operation in the third quarter of 2021. The initial lease term is eight years. Fixed rent payments under the initial term are approximately $620,000. The Company has surrendered possession of the property and is currently in negotiations for the amounts owed and is in the process of settling the remaining amounts owed.

 

Maple Grove Clinic a.k.a. Arbor Lakes

 

On October 8, 2021, we entered into an agreement to open a clinic in Maple Grove, Minnesota which began operation in the fourth quarter of 2021. The initial lease term is for 108 months. Fixed rent payments under the initial term are approximately $1,153,127. On October 22, 2022, the Company entered into a settlement agreement with the leaseholder for $219,576 and the Company released the property back to the leaseholder.

 

Radiant Clinic a.k.a. LMC Welton

 

On September 9, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 90 months. Fixed rent payments under the initial term are approximately $782,000. As of April 10, 2024, the Company has settled the amounts owed to the leaseholder and full resolution of all liens for approximately $530,000 and the Company has released the property back to the leaseholder.

 

Quincy Clinic a.k.a. 1776 Curtis

 

On September 28, 2021, we entered into an agreement to open a clinic in Denver, Colorado, which was expected to begin operation in the first quarter of 2023 but possession of which has been relinquished to the landlords. The initial lease term is for 94 months. Fixed rent payments under the initial term are approximately $1,079,000. A Final Judgment was granted on November 14, 2023, in the amount of $348,764 including interest, fees and other costs. The Company has released the property back to the leaseholder.

 

The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

 

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,768

 

 

 

Administrative offices

 

On June 24, 2021, we entered into an agreement to open an administrative office in St. Louis Park, Minnesota. The initial lease term is 2.5 years. Fixed rent payments under the initial term are approximately $244,000. We have not received any claims as to the obligations under this sublease agreement and the business from which we were renting has not responded to communications from our attorneys who have attempted to establish a formal settlement agreement since we have abandoned the location more than a year ago.

v3.24.2.u1
Subsequent Events
6 Months Ended
Jun. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events [Text Block]

Note 14: Subsequent Events

 

On July 18, 2024, in one case, and July 19, 2024, for the other two cases, the Company entered into a lending agreement with each of three (3) of its historical institutional investors, Cavalry Fund, AJB and Mercer Street Capital (“the Lenders”). The notes provide $25,000 of proceeds each, are for a 12-month period, and earn interest at ten percent (10%) per year.

 

On July 29, 2024, the Board of Directors approved a consulting agreement which was effective July 8, 2024, with Brian Valania, to manage sales and marketing for the Centcore, LLC business unit. Mr. Valania replaces Ms. Betsy Berlin who was engaged in May 2024 and terminated by mutual consent in June 2024, with a total cost of $10,000. His compensation includes a monthly fee of $11,250, and additional compensation to be determined based on the achievement of certain business goals of up to $135,000 per year. He was also issued 200,000 shares of restricted common stock of which 100,000 is considered immediately earned, 50,000 are considered earned as of December 31, 2024, and the final 50,000 are considered earned as of June 30, 2024. His continued employment is among the conditions for earning the shares discussed herein. The Company will realize a charge of $50,000 in the 3rd quarter of 2024 for this issuance, which was expensed at $.25 per share.

 

On July 29, 2024, the Company issued 100,000 of restricted common stock to each of its three (3) directors in consideration of their contribution to operations beyond the scope of their responsibilities on the Board. The issuance of 300,000 shares in aggregate will result in a charge during the 3rd quarter of 2024 of $75,000 in total, using a valuation of $.25 per share.

v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure            
Net Income (Loss) $ (412,445) $ 46,524 $ (7,544,270) $ (5,613,825) $ (365,921) $ (13,158,095)
v3.24.2.u1
Insider Trading Arrangements
6 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.2.u1
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation – The consolidated financial statements are prepared in conformity with accounting principles accepted in the United States of America (“GAAP”).

The consolidated financial statements and related disclosures as of June 30, 2024, are unaudited, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. In our opinion, these unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited financial statements should be read in conjunction with the audited financial statements of the Company for the years ended December 31, 2023, and 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024. The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year ended December 31, 2024.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation The accompanying consolidated financial statements include the accounts of Mitesco, Inc., and its wholly owned subsidiaries Mitesco NA, LLC, The Good Clinic, LLC, Vero Technology Ventures, LLC, and Centcore, LLC. In addition, we relied on the operating activities of certain legal entities in which we did not maintain a controlling ownership interest, but over which we had indirect influence and of which we were considered the primary beneficiary. These entities are typically subject to nominee ownership and transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. The Company’s management, restriction and other agreements concerning such nominee-owned entities typically includes both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for these entities to the Company. As such, the Company applies the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 – Consolidation (“ASC 810”), to determine when an entity that is insufficiently capitalized or not controlled through its voting interests, referred to as a variable interest entity should be consolidated. All intercompany balances and transactions have been eliminated.

Earnings Per Share, Policy [Policy Text Block]

Per Share Data - Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options, and convertible instruments. For the three and six months ended June 30, 2024, the effect of 673,208 warrants to purchase shares of common stock, 13,667 options to purchase shares of common stock, and 1,216,616 shares of common stock issuable upon conversion of Series D preferred stock were excluded from the calculation of net loss per share as their effect was antidilutive. For the three and six months ended June 30, 2023 the effect of 673,208 warrants to purchase shares of common stock, 209,381 options to purchase shares of common stock, and 3,467,464 shares of common stock issuable upon conversion of Series D preferred stock were excluded from the calculation of net loss per share as their effect was antidilutive.

Discontinued Operations, Policy [Policy Text Block]

Discontinued Operations - The accompanying financial statements are prepared with the guidance of ASU 2014-08, “Reporting Discontinued Operations”, and ASC Topic 205, Presentation of Financial Statements, and ASC Topic 360, Property, Plant and Equipment.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Standards – In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.

There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

v3.24.2.u1
Discontinued Operations (Tables)
6 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations [Table Text Block] The following information presents the major classes of line items constituting the after-tax loss from discontinued operations in the consolidated statements of operations:
   

Three Months Ended

   

Six Months Ended

 
   

June 30,

   

June 30,

   

June 30,

   

June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Revenue

  $ -     $ -     $ -     $ -  

Cost of goods sold

    -       5,601       -       8,020  

Gross margin

            (5,601 )     -       (8,020 )
                                 

Selling, general, and administrative expenses

    -       (216,404 )     -       (597,905 )

Impairment of assets

    -       (68,034 )     -       (2,211,462 )
                                 

Other (income) expense:

                               

Gain on termination of operating lease

    -       -       -       287,897  

Interest expense

    -       (83,720 )     -       (169,313 )

Loss from discontinued operations, net of tax

  $ -     $ (373,759 )   $ -     $ (2,698,803 )
   

Six Months Ended

 
   

June 30,

   

June 30,

 
   

2024

   

2023

 
                 

Depreciation expense

  $ -     $ 81,764  

Impairment of property and equipment

  $ -     $ 2,211,462  

Changes in accounts payable and accrued liabilities

  $ -     $ 444,884  
v3.24.2.u1
Accounts Payable and Accrued Liabilities (Tables)
6 Months Ended
Jun. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounts payable and accrued liabilities consisted of the following at June 30, 2024, and December 31, 2023:
   

June 30,

   

December 31,

 
   

2024

   

2023

 

Trade accounts payable

  $ 6,516,812     $ 7,094,334  

Accrued payroll and payroll taxes

    833,495       743,778  

Total accounts payable and accrued liabilities

  $ 7,350,307     $ 7,838,112  
v3.24.2.u1
Right to Use Assets and Lease Liabilities – Operating Leases (Tables)
6 Months Ended
Jun. 30, 2024
Disclosure Text Block [Abstract]  
Lease, Cost [Table Text Block] Operating lease liabilities are summarized below:
   

June 30 30,

2024

   

December 31,

2023

 

Lease liability

  $ 99,477     $ 99,477  

Less: current portion

    (99,477 )     (99,477 )

Lease liability, non-current

  $ -     $ -  
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] As a result of closing the facilities, the Company has made no further lease payments during the year ending December 31, 2023, or the six months ending June 30, 2024. As of June 30, 2024, the Company has either settled amounts owed or entered into default judgements for all leases except for the office lease, which we believe is nominal. For all leases for which a legal settlement has been entered into, all amounts have been reclassified to legal settlements as of June 30, 2024, and December 31, 2023.

For the period ended December 31, 2024

  $ 99,477  

For the period ended December 31, 2025

    -  

For the period ended December 31, 2026

    -  

For the period ended December 31, 2027

    -  

For the period ended December 31, 2028

    -  

Thereafter

    -  

Total

  $ 99,477  

Less: Present value discount

    -  

Lease liability

  $ 99,477  
v3.24.2.u1
Notes Payable (Tables)
6 Months Ended
Jun. 30, 2024
Notes Payable (Tables) [Line Items]  
Schedule of Debt [Table Text Block] The following table summarizes the outstanding notes payable as of June 30, 2024, and December 31, 2023, respectively:
   

June 30, 2024

   

December 31, 2023

 

Kishon Note

  $ 431,666     $ 431,666  

Finnegan Note 1

    51,765       51,765  

Finnegan Note 2

    32,353       32,353  

Schrier Note

    25,882       25,882  

Nommsen Note

    64,705       64,705  

Caplan Note

    64,705       64,705  

Finnegan Note 3

    32,353       32,353  

Lightmas Note

    66,000       66,000  

Lewis Note

    33,000       33,000  

Goff Note

    33,000       33,000  

Hagan Note

    110,000       110,000  

Cavalry Note 1

    25,000       -  

Cavalry Note 2

    50,000       -  

Mercer Note 1

    25,000       -  

Mercer Note 2

    50,000       -  

ABJ Note

    50,000       -  

Cavalry Note 3

    33,000       -  

Mercer Note 3

    33,000       -  

ABJ Note 2

    33,000       -  

Notes Payable

    1,244,429       945,429  
                 

Current Portion

    1,244,429       945,429  

Long-term portion

  $ -     $ -  
Related Party [Member]  
Notes Payable (Tables) [Line Items]  
Schedule of Debt [Table Text Block] The following table summarizes the outstanding related party notes payable as of June 30, 2024, and December 31, 2023, respectively.
   

June 30,

2024

   

December 31,

2023

 

M Diamond Note

    64,706       64,706  

Dobbertin Note

    19,412       19,412  

Lindstrom Note

    45,294       45,294  

Mitchell Note

    78,100       78,100  

Leath Note

    55,000       55,000  

November 29, 2022, Notes

    37,500       37,500  

Notes Payable

    300,012       300,012  
                 

Current Portion, net of discount

  $ 300,012     $ 300,012  

Long-term portion, net of discount

    -       -  

 

v3.24.2.u1
Derivative Liabilities (Tables)
6 Months Ended
Jun. 30, 2024
Disclosure Text Block [Abstract]  
Schedule of Derivative Instruments [Table Text Block] Derivative liability activity for the six months ended June 30, 2024, is summarized in the table below:

December 31, 2023

  $ 152,945  

True-up features issued

    -  

Settled upon conversion or exercise

    -  

Loss on revaluation

    -  

June 30, 2024

  $ 152,945  
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following tables summarize the assumptions for the valuations:
   

June 30,

   

December 31,

 
   

2024

   

2023

 

Volatility

    475.7 %     475.7 %

Stock Price

  $ 0.0250     $ 0.0250  

Risk-free interest rates

    5.21 %     5.21 %

Term (years)

    0.39       0.39  

 

v3.24.2.u1
Stockholders' Equity (Deficit) (Tables)
6 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] The following table summarizes the options outstanding at June 30, 2024, and the related prices for the options to purchase shares of the Company’s common stock:
                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

options

   

contractual

   

outstanding

   

options

   

exercisable

 

prices

   

outstanding

   

life (years)

   

options

   

exercisable

   

options

 
$ 1.50       13,667       5.79     $ 1.50       13,667     $ 1.50  
          13,667       5.79     $ 1.50       13,667     $ 1.50  

 

Share-Based Payment Arrangement, Option, Activity [Table Text Block] The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:
   

Shares

   

Weighted- Average

Exercise Price ($)

 

Outstanding at December 31, 2023

    100,934     $ 10.01  

Granted

    -       -  

Cancelled/Expired

    (87,267 )   $ 11.38  

Exercised

    -       -  

Outstanding at June 30, 2024

    13,667     $ 1.50  

Options vested and exercisable

    13,667     $ 1.50  
Schedule Of Warrant Purchase Exercise Price Range [Table Text Block] The following table summarizes the warrants outstanding on June 30, 2024, and the related prices for the warrants to purchase shares of the Company’s common stock:
                       

Weighted

           

Weighted

 
               

Weighted

   

average

           

average

 
               

average

   

exercise

           

exercise

 

Range of

   

Number of

   

remaining

   

price of

   

Number of

   

price of

 

exercise

   

warrants

   

contractual

   

outstanding

   

warrants

   

exercisable

 

prices

   

outstanding

   

life (years)

   

warrants

   

exercisable

   

warrants

 
$ 2.50       874       3.81     $ 2.5       874     $ 2.5  
  25.00       366,784       2.23       25.00       366,784       25.00  
  37.50       305,550       2.11       37.50       305,550       37.50  
          673,208       2.17     $ 30.64       673,208     $ 30.64  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] The following table summarizes the transactions involving options to purchase shares of the Company’s common stock:
   

Shares

   

Weighted- Average

Exercise Price ($)

 
                 

Outstanding at December 31, 2023

    673,208     $ 30.64  

Granted

    -     $ -  

Exercised

    -     $ -  

Outstanding at June 30, 2024

    673,208     $ 30.64  
v3.24.2.u1
Fair Value of Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Derivative Liabilities at Fair Value [Table Text Block] The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at June 30, 2024, and December 31, 2023.
   

June 30, 2024

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  
   

December 31, 2023

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Liabilities

                               

Derivative liabilities

  $ -     $ -     $ 152,945     $ 152,945  
v3.24.2.u1
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Property Settlement Obligations [Table Text Block] The following table summarizes the status of our property settlements as noted above and the total settlement amounts as of the date of the filing:

LOCATION

 

ALSO KNOWN AS:

 

PROPERTY NAME/OWNER

 

ORIGINAL OBLIGATION

(NOT INC. CAPX)

 

 

SETTLEMENT AMOUNT

 

TYPE OF SETTLEMENT

MINNEAPOLIS, MN

 

NORDHAUS

 

LENNAR

 

$

511,000

 

 

$

-

 

N.A.

WAYZETTA, MN

 

PROMINADE

 

WAZETTA BAY

 

$

407,000

 

 

$

25,000

 

CASH PAYMENT OBLIGATION

EAGAN, MN

 

EAGAN CLINIC

 

VIKINGS

 

$

767,000

 

 

$

488,491

 

DEFAULT JUDGEMENT

ST. LOUIS PARK, MN

 

EXCELSIOR & GRAND

 

EXCELSIOR

 

$

673,000

 

 

$

425,350

 

DEFAULT JUDGEMENT

ST. PAUL, MN

 

THE GROVE

 

CONTINENTAL 560

 

$

1,153,000

 

 

$

415,606

 

DEFAULT JUDGEMENT

EDEN PRARIE

 

ELEVATE

 

TP ELEVATE

 

$

620,000

 

 

$

-

 

IN PROCESS

MAPLE GROVE, MN

 

ARBOR LAKES

 

BUTTNICK

 

$

1,153,127

 

 

$

219,575

 

SETTLEMENT AGREE

DENVER, CO

 

LMC WELTON

 

RADIANT

 

$

782,000

 

 

$

530,000

 

DEFAULT JUDGEMENT

DENVER, CO

 

1776 CURTIS

 

QUINCY

 

$

1,079,000

 

 

$

348,764

 

DEFAULT JUDGEMENT

 

 

 

 

TOTAL

 

$

7,145,127

 

 

$

2,452,768

 

 

v3.24.2.u1
Going Concern (Details) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and Cash Equivalents, at Carrying Value $ 40,196 $ 2,838
Liabilities, Current $ 15,184,831 $ 14,134,595
v3.24.2.u1
Summary of Significant Accounting Policies (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Warrant [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 673,208 673,208 673,208 673,208
Share-Based Payment Arrangement, Option [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 13,667 209,381 13,667 209,381
Series D Preferred Stock [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,216,616 3,467,464 1,216,616 3,467,464
v3.24.2.u1
Discontinued Operations (Details)
$ in Millions
Dec. 08, 2023
USD ($)
Discontinued Operations and Disposal Groups [Abstract]  
Proceeds from Sale of Productive Assets $ 2.5
v3.24.2.u1
Discontinued Operations (Details) - Disposal Groups, Including Discontinued Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disposal Groups Including Discontinued Operations Abstract        
Revenue $ 0 $ 0 $ 0 $ 0
Cost of goods sold 0 5,601 0 8,020
Gross margin 0 (5,601) 0 (8,020)
Selling, general, and administrative expenses 0 (216,404) 0 (597,905)
Impairment of assets 0 (68,034) 0 (2,211,462)
Gain on termination of operating lease 0 0 0 287,897
Interest expense 0 (83,720) 0 (169,313)
Loss from discontinued operations, net of tax $ 0 $ (373,759) 0 (2,698,803)
Depreciation expense     0 81,764
Impairment of property and equipment     0 2,211,462
Changes in accounts payable and accrued liabilities     $ 0 $ 444,884
v3.24.2.u1
Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Schedule Of Accounts Payable And Accrued Liabilities Abstract    
Trade accounts payable $ 6,516,812 $ 7,094,334
Accrued payroll and payroll taxes 833,495 743,778
Total accounts payable and accrued liabilities $ 7,350,307 $ 7,838,112
v3.24.2.u1
Right to Use Assets and Lease Liabilities – Operating Leases (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Disclosure Text Block [Abstract]          
Estimated Litigation Liability, Current $ 2,452,768   $ 2,452,768   $ 2,219,886
Gain (Loss) on Termination of Lease $ 0 $ 0 $ 233,205 $ 0  
v3.24.2.u1
Right to Use Assets and Lease Liabilities – Operating Leases (Details) - Lease, Cost - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Lease, Cost [Abstract]    
Lease liability $ 99,477 $ 99,477
Less: current portion (99,477) (99,477)
Lease liability, non-current $ 0 $ 0
v3.24.2.u1
Right to Use Assets and Lease Liabilities – Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Dec. 15, 2023
Nov. 14, 2023
Oct. 14, 2021
Oct. 08, 2021
Sep. 28, 2021
Sep. 21, 2021
Jun. 08, 2021
May 04, 2021
Nov. 01, 2020
Lessee Operating Lease Liability Maturity Abstract                      
For the period ended December 31, 2024 $ 99,477                    
For the period ended December 31, 2025 0                    
For the period ended December 31, 2026 0                    
For the period ended December 31, 2027 0                    
For the period ended December 31, 2028 0                    
Thereafter 0                    
Total 99,477   $ 1,153,000 $ 244,000 $ 767,000 $ 1,153,127 $ 1,079,000 $ 782,000 $ 620,000 $ 673,000 $ 511,000
Less: Present value discount 0                    
Lease liability $ 99,477 $ 99,477                  
v3.24.2.u1
SBA Loan Payable (Details) - USD ($)
6 Months Ended 12 Months Ended
Jul. 12, 2023
Jun. 30, 2024
Dec. 31, 2023
May 04, 2020
SBA Loan Payable (Details) [Line Items]        
Debt Instrument, Periodic Payment $ 2,595      
Loans Payable to Bank $ 467,117      
Notes Payable   $ 1,244,429 $ 945,429  
PPP Loan [Member]        
SBA Loan Payable (Details) [Line Items]        
Debt Instrument, Face Amount       $ 460,400
Debt Instrument, Interest Rate, Effective Percentage     1.00% 1.00%
Gains (Losses) on Restructuring of Debt     $ 40,622  
Notes Payable     $ 433,343  
Repayments of Debt   13,485    
Accrued Interest [Member] | PPP Loan [Member]        
SBA Loan Payable (Details) [Line Items]        
Repayments of Debt   $ 2,087    
v3.24.2.u1
Notes Payable (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
May 15, 2024
May 13, 2024
Feb. 28, 2024
Jan. 23, 2024
Dec. 08, 2023
Sep. 29, 2023
Nov. 29, 2022
Sep. 15, 2022
Sep. 02, 2022
Aug. 04, 2022
Jul. 27, 2022
Jul. 26, 2022
Jul. 07, 2022
Jun. 09, 2022
May 26, 2022
May 23, 2022
May 10, 2022
Dec. 30, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                                         0      
Derivative Liability, Current                                     $ 152,945   $ 152,945   $ 152,945  
Proceeds from Issuance of Debt                                         $ 299,000 $ 0    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                                     $ 30.64   $ 30.64   $ 30.64  
Warrants and Rights Outstanding                                     $ 673,208   $ 673,208      
Interest Expense, Debt                                         108,227      
Debt Related Commitment Fees and Debt Issuance Costs                                     0 $ 6,429,107 0 6,429,107    
Kishon Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                                 $ 159,259              
Stock Issued During Period, Shares, Other (in Shares)                                 12,741              
Class of Warrant or Rights, Granted (in Shares)                                 5,556              
Derivative Liability, Current                                 $ 27,793              
Debt Instrument, Face Amount                                 277,777              
Proceeds from Issuance of Debt                                 250,000              
Debt Instrument, Unamortized Discount                                 $ 138,492              
Debt Instrument, Maturity Date                                 Nov. 10, 2022              
Debt Instrument, Interest Rate, Stated Percentage                                 12.00%              
Debt Instrument, Fee Amount                                             $ 15,000  
Debt Instrument, Debt Default, Amount                                     431,666   431,666   431,666  
Interest Payable                                     127,653   127,653   88,909  
Finnegan Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                               $ 3,240                
Stock Issued During Period, Shares, Other (in Shares)                               1,930                
Debt Instrument, Face Amount                               $ 47,059                
Proceeds from Issuance of Debt                               $ 40,000                
Debt Instrument, Maturity Date                               Nov. 20, 2022                
Debt Instrument, Debt Default, Amount                                     51,765   51,765   51,765  
Interest Payable                                     16,142   16,142   11,889  
Warrants and Rights Outstanding                               $ 2,000                
Finnegan Note 1 [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                               386                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                               $ 25                
Finnegan Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                             $ 2,025                  
Stock Issued During Period, Shares, Other (in Shares)                             242                  
Debt Instrument, Face Amount                             $ 29,412                  
Proceeds from Issuance of Debt                             $ 25,000                  
Debt Instrument, Maturity Date                             Nov. 30, 2022                  
Debt Instrument, Debt Default, Amount                                     32,353   32,353   32,353  
Interest Payable                                     9,999   9,999   7,341  
Warrants and Rights Outstanding                             $ 1,250                  
Finnegan Note 2 [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                             242                  
Share Price (in Dollars per share)                             $ 25                  
Schrier Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                         $ 1,000                      
Stock Issued During Period, Shares, Other (in Shares)                         193                      
Class of Warrant or Rights, Granted (in Shares)                         193                      
Debt Instrument, Face Amount                         $ 23,259                      
Proceeds from Issuance of Debt                         $ 20,000                      
Debt Instrument, Maturity Date                         Jan. 08, 2023                      
Debt Instrument, Interest Rate, Stated Percentage                         10.00%                      
Debt Instrument, Debt Default, Amount                                     25,882   25,882   25,882  
Interest Payable                                     7,510   7,510   5,383  
Warrants and Rights Outstanding                         $ 820                      
Schrier Note [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                         $ 25                      
Nommsen Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                       $ 2,350                        
Stock Issued During Period, Shares, Other (in Shares)                       483                        
Debt Instrument, Face Amount                       $ 58,823                        
Proceeds from Issuance of Debt                       $ 50,000                        
Debt Instrument, Maturity Date                       Nov. 30, 2022                        
Debt Instrument, Interest Rate, Stated Percentage                       10.00%                        
Debt Instrument, Debt Default, Amount                                     64,705   64,705   64,705  
Interest Payable                                     19,001   19,001   13,685  
Warrants and Rights Outstanding                       $ 1,850                        
Nommsen Note [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                       483                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                       $ 25                        
Caplan Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                     $ 2,350                          
Stock Issued During Period, Shares, Other (in Shares)                     483                          
Debt Instrument, Face Amount                     $ 58,823                          
Proceeds from Issuance of Debt                     $ 50,000                          
Debt Instrument, Maturity Date                     Jan. 21, 2023                          
Debt Instrument, Interest Rate, Stated Percentage                     10.00%                          
Debt Instrument, Debt Default, Amount                                     64,705   64,705   64,705  
Interest Payable                                     18,305   18,305   12,989  
Warrants and Rights Outstanding                     $ 1,850                          
Caplan Note [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                     483                          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                     $ 25                          
Finnegan Note 3 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                   $ 1,100                            
Stock Issued During Period, Shares, Other (in Shares)                   242                            
Debt Instrument, Face Amount                   $ 29,412                            
Proceeds from Issuance of Debt                   $ 25,000                            
Debt Instrument, Maturity Date                   Feb. 03, 2023                            
Debt Instrument, Interest Rate, Stated Percentage                   10.00%                            
Debt Instrument, Debt Default, Amount                                     32,353   32,353   32,353  
Interest Payable                                     9,008   9,008   6,350  
Warrants and Rights Outstanding                   $ 850                            
Finnegan Note 3 [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                   242                            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                   $ 25                            
Lightmas Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                 $ 2,640                              
Stock Issued During Period, Shares, Other (in Shares)                 492                              
Debt Instrument, Face Amount                 $ 60,000                              
Proceeds from Issuance of Debt                 $ 51,000                              
Debt Instrument, Maturity Date                 Nov. 30, 2022                              
Debt Instrument, Interest Rate, Stated Percentage                 10.00%                              
Debt Instrument, Debt Default, Amount                                     66,000   66,000   66,000  
Interest Payable                                     18,748   18,748   13,325  
Lewis Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                 $ 1,320                              
Stock Issued During Period, Shares, Other (in Shares)                 246                              
Debt Instrument, Face Amount                 $ 30,000                              
Proceeds from Issuance of Debt                 $ 25,500                              
Debt Instrument, Maturity Date                 Nov. 30, 2022                              
Debt Instrument, Interest Rate, Stated Percentage                 10.00%                              
Debt Instrument, Debt Default, Amount                                     33,000   33,000   33,000  
Interest Payable                                     9,374   9,374   6,663  
Goff Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                 $ 1,320                              
Stock Issued During Period, Shares, Other (in Shares)                 246                              
Debt Instrument, Face Amount                 $ 30,000                              
Proceeds from Issuance of Debt                 $ 25,500                              
Debt Instrument, Maturity Date                 Nov. 30, 2022                              
Debt Instrument, Interest Rate, Stated Percentage                 10.00%                              
Debt Instrument, Debt Default, Amount                                     33,000   33,000   33,000  
Interest Payable                                     9,374   9,374   6,663  
Hagan Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                 $ 4,715                              
Stock Issued During Period, Shares, Other (in Shares)                 820                              
Debt Instrument, Face Amount                 $ 100,000                              
Proceeds from Issuance of Debt                 $ 85,000                              
Debt Instrument, Maturity Date                 Dec. 10, 2022                              
Debt Instrument, Interest Rate, Stated Percentage                 10.00%                              
Debt Instrument, Debt Default, Amount                                     110,000   110,000   110,000  
Interest Payable                                     30,831   30,831   21,793  
Cavalry Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount       $ 25,000                                        
Debt Instrument, Interest Rate, Stated Percentage       10.00%                                        
Debt Instrument, Debt Default, Amount                                     25,000   25,000      
Interest Payable                                     1,587   1,587      
Cavalry Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount     $ 50,000                                          
Debt Instrument, Interest Rate, Stated Percentage     10.00%                                          
Debt Instrument, Debt Default, Amount                                     50,000   50,000      
Interest Payable                                     2,688   2,688      
Cavalry Note 3 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount   $ 33,000                                            
Debt Instrument, Maturity Date   May 13, 2025                                            
Debt Instrument, Interest Rate, Stated Percentage   10.00%                                            
Debt Instrument, Debt Default, Amount                                     50,000   50,000      
Interest Payable                                     434   434      
Mercer Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount       $ 25,000                                        
Debt Instrument, Maturity Date       Jan. 23, 2025                                        
Debt Instrument, Interest Rate, Stated Percentage       10.00%                                        
Debt Instrument, Debt Default, Amount                                     25,000   25,000      
Interest Payable                                     1,587   1,587      
Mercer Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount     $ 50,000                                          
Debt Instrument, Maturity Date     Feb. 28, 2025                                          
Debt Instrument, Interest Rate, Stated Percentage     10.00%                                          
Debt Instrument, Debt Default, Amount                                     50,000   50,000      
Interest Payable                                     2,675   2,675      
Mercer Note 3 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount   $ 33,000                                            
Debt Instrument, Maturity Date   May 13, 2025                                            
Debt Instrument, Interest Rate, Stated Percentage   10.00%                                            
Debt Instrument, Debt Default, Amount                                     50,000   50,000      
Interest Payable                                     416   416      
AJB Capital Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount     $ 50,000                                          
Debt Instrument, Maturity Date     Feb. 28, 2025                                          
Debt Instrument, Interest Rate, Stated Percentage     10.00%                                          
Debt Instrument, Debt Default, Amount                                     50,000   50,000      
Interest Payable                                     2,605   2,605      
AJB Capital Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount $ 50,000                                              
Debt Instrument, Maturity Date May 15, 2025                                              
Debt Instrument, Interest Rate, Stated Percentage 10.00%                                              
Debt Instrument, Debt Default, Amount                                     50,000   50,000      
Interest Payable                                     416   416      
Notes Payable, Other Payables [Member]                                                
Notes Payable (Details) [Line Items]                                                
Interest Payable, Current                                     449,455   449,455   348,821  
M Diamond Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                             $ 4,050                  
Stock Issued During Period, Shares, Other (in Shares)                             483                  
Debt Instrument, Face Amount                             $ 58,823                  
Proceeds from Issuance of Debt                             $ 50,000                  
Debt Instrument, Maturity Date                             Nov. 30, 2022                  
Debt Instrument, Interest Rate, Stated Percentage                             10.00%                  
Debt Instrument, Debt Default, Amount                                     64,706   64,706   64,706  
Interest Payable                                     17,636   17,636   14,682  
Warrants and Rights Outstanding                             $ 2,500                  
M Diamond Note [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)                             483                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                             $ 25                  
Dobbertin Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                             $ 1,215                  
Stock Issued During Period, Shares, Other (in Shares)                             145                  
Class of Warrant or Rights, Granted (in Shares)                             145                  
Debt Instrument, Face Amount                             $ 17,647                  
Proceeds from Issuance of Debt                             $ 15,000                  
Debt Instrument, Maturity Date                             Nov. 30, 2022                  
Debt Instrument, Interest Rate, Stated Percentage                             10.00%                  
Debt Instrument, Debt Default, Amount                                     19,412   19,412   19,412  
Interest Payable                                     5,989   5,989   4,405  
Warrants and Rights Outstanding                             $ 750                  
Dobbertin Note 1 [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                             $ 25                  
Lindstrom Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                             $ 2,835                  
Stock Issued During Period, Shares, Other (in Shares)                             338                  
Class of Warrant or Rights, Granted (in Shares)                             338                  
Debt Instrument, Face Amount                             $ 41,176                  
Proceeds from Issuance of Debt                             $ 35,000                  
Debt Instrument, Maturity Date                             Nov. 30, 2022                  
Debt Instrument, Interest Rate, Stated Percentage                             10.00%                  
Debt Instrument, Debt Default, Amount                                     45,294   45,294   45,294  
Interest Payable                                     13,973   13,973   10,277  
Warrants and Rights Outstanding                             $ 1,750                  
Lindstrom Note 1 [Member] | Warrants at $25.00 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)                             $ 25                  
Mitchell Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Face Amount                           $ 71,000                    
Proceeds from Issuance of Debt                                   $ 60,350            
Debt Instrument, Maturity Date                           Nov. 30, 2022                    
Debt Instrument, Interest Rate, Stated Percentage                                   10.00%            
Debt Instrument, Debt Default, Amount                                     78,100   78,100   78,100  
Interest Payable                                     22,185   22,185   15,768  
Leath Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other               $ 2,868                                
Stock Issued During Period, Shares, Other (in Shares)               410                                
Debt Instrument, Face Amount               $ 50,000                                
Proceeds from Issuance of Debt               $ 42,500                                
Debt Instrument, Maturity Date               Dec. 15, 2022                                
Debt Instrument, Interest Rate, Stated Percentage               10.00%                                
Debt Instrument, Debt Default, Amount                                     55,000   55,000   55,000  
Interest Payable                                     15,276   15,276   10,757  
November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Class of Warrant or Rights, Granted (in Shares)             750                                  
Debt Instrument, Unamortized Discount                                               $ 3,083
Debt Instrument, Maturity Date             May 28, 2023                                  
Debt Instrument, Debt Default, Amount                                     37,500   37,500   37,500 18,750
Interest Payable                                     7,785   7,785   5,903 164
Amortization of Debt Discount (Premium)                                               $ 667
Debt Instrument, Increase, Accrued Interest                                             11,967  
Debt Conversion, Converted Instrument, Shares Issued (in Shares)           26,064                                    
Debt Related Commitment Fees and Debt Issuance Costs           $ 13,553                                    
Debt Instrument, Convertible, Conversion Price (in Dollars per share)           $ 0.8                                    
Investment Incentive [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount           $ 13,553                                    
Convertible Notes Payable [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount           18,750                                    
Convertible Notes Payable [Member] | Howe Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount         $ 18,750                                      
Accrued Interest [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount           2,101                                    
Accrued Interest [Member] | Howe Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount         $ 2,682                                      
Minimum [Member] | Kishon Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                                 10.00%              
Measurement Input, Default Rate [Member] | Kishon Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                                 18.00%              
Measurement Input, Default Rate [Member] | Finnegan Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                               18.00%                
Measurement Input, Default Rate [Member] | Finnegan Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                             18.00%                  
Measurement Input, Default Rate [Member] | Schrier Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                         18.00%                      
Measurement Input, Default Rate [Member] | Nommsen Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                       18.00%                        
Measurement Input, Default Rate [Member] | Caplan Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                     18.00%                          
Measurement Input, Default Rate [Member] | Finnegan Note 3 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                   18.00%                            
Measurement Input, Default Rate [Member] | Lightmas Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                 18.00%                              
Measurement Input, Default Rate [Member] | Lewis Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                 18.00%                              
Measurement Input, Default Rate [Member] | Goff Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                 18.00%                              
Measurement Input, Default Rate [Member] | Hagan Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                 18.00%                              
Measurement Input, Default Rate [Member] | Cavalry Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage       12.00%                                        
Measurement Input, Default Rate [Member] | Cavalry Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage     12.00%                                          
Measurement Input, Default Rate [Member] | Cavalry Note 3 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage   12.00%                                            
Measurement Input, Default Rate [Member] | Mercer Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage       12.00%                                        
Measurement Input, Default Rate [Member] | Mercer Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage     12.00%                                          
Measurement Input, Default Rate [Member] | Mercer Note 3 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage               12.00%                                
Measurement Input, Default Rate [Member] | AJB Capital Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage     12.00%                                          
Measurement Input, Default Rate [Member] | AJB Capital Note 2 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage 12.00%                                              
Measurement Input, Default Rate [Member] | M Diamond Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                             18.00%                  
Measurement Input, Default Rate [Member] | Dobbertin Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                             18.00%                  
Measurement Input, Default Rate [Member] | Lindstrom Note 1 [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                             18.00%                  
Measurement Input, Default Rate [Member] | Mitchell Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage                                   18.00%            
Measurement Input, Default Rate [Member] | Leath Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage               18.00%                                
Measurement Input, Default Rate [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Interest Rate, Stated Percentage             18.00%                                  
Related Party [Member]                                                
Notes Payable (Details) [Line Items]                                                
Interest Payable                                     82,845   82,845   61,792  
Interest Expense, Debt                                         15,546      
Interest Payable, Current                                     $ 82,845   82,845   61,792  
Amortization of Debt Discount (Premium)                                         $ 0 $ 19,617    
Original Issue Discount [Member] | Kishon Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Unamortized Discount                                 $ 27,777              
Default Penalty [Member] | Kishon Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Instrument, Fee Amount                                             $ 138,889  
Warrants at $25.00 [Member] | Mitchell Note [Member]                                                
Notes Payable (Details) [Line Items]                                                
Stock Issued During Period, Value, Other                                   $ 3,124            
Stock Issued During Period, Shares, Other (in Shares)                                   582            
Series F Preferred Stock [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount           $ 34,404                                    
Debt Conversion, Converted Instrument, Shares Issued (in Shares)           34                                    
Series F Preferred Stock [Member] | Convertible Notes Payable [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount           $ 18,750                                    
Series F Preferred Stock [Member] | Accrued Interest [Member] | November 29, 2022 Notes [Member]                                                
Notes Payable (Details) [Line Items]                                                
Debt Conversion, Original Debt, Amount           $ 2,101                                    
v3.24.2.u1
Notes Payable (Details) - Schedule of Debt - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes payable - net of discount $ 1,244,429 $ 945,429
Current Portion, net of discount 1,244,429 945,429
Long-term portion, net of discount 0 0
Kishon Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 431,666 431,666
Finnegan Note 1 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 51,765 51,765
Finnegan Note 2 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 32,353 32,353
Schrier Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 25,882 25,882
Nommsen Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 64,705 64,705
Caplan Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 64,705 64,705
Finnegan Note 3 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 32,353 32,353
Lightmas Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 66,000 66,000
Lewis Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 33,000 33,000
Goff Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 33,000 33,000
Hagan Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 110,000 110,000
Cavalry Note 1 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 25,000 0
Cavalry Note 2 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 50,000 0
Mercer Note 1 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 25,000 0
Mercer Note 2 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 50,000 0
AJB Capital Note [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 50,000 0
Cavalry Note 3 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 33,000 0
Mercer Note 3 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable 33,000 0
AJB Capital Note 2 [Member]    
Notes Payable (Details) - Schedule of Debt [Line Items]    
Notes Payable $ 33,000 $ 0
v3.24.2.u1
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties - Related Party [Member] - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes payable – net of discounts $ 300,012 $ 300,012
Current Portion, net of discount 300,012 300,012
Long-term portion, net of discount 0 0
M Diamond Note [Member]    
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable 64,706 64,706
Dobbertin Note 1 [Member]    
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable 19,412 19,412
Lindstrom Note 1 [Member]    
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable 45,294 45,294
Mitchell Note [Member]    
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable 78,100 78,100
Leath Note [Member]    
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable 55,000 55,000
November 29, 2022 Notes [Member]    
Notes Payable – Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]    
Notes Payable $ 37,500 $ 37,500
v3.24.2.u1
Derivative Liabilities (Details) - Schedule of Derivative Liability Acitivity
6 Months Ended
Jun. 30, 2024
USD ($)
Schedule Of Derivative Liability Acitivity Abstract  
Balance $ 152,945
True-up features issued 0
Settled upon conversion or exercise 0
Loss on revaluation 0
Balance $ 152,945
v3.24.2.u1
Derivative Liabilities (Details) - Schedule of Valuation Assumptions - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Schedule Of Valuation Assumptions Abstract    
Volatility 475.70% 475.70%
Stock Price (in Dollars per share) $ 0.025 $ 0.025
Risk-free interest rates 5.21% 5.21%
Term (years) 4 months 20 days 4 months 20 days
v3.24.2.u1
Stockholders' Equity (Deficit) (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 27, 2024
Mar. 20, 2024
Feb. 09, 2024
Jul. 01, 2023
Nov. 07, 2022
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Mar. 23, 2023
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Common Stock, Shares Authorized               500,000,000   500,000,000  
Common Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01   $ 0.01  
Common Stock, Shares, Issued               5,958,582   5,567,957  
Common Stock, Shares, Outstanding               5,958,582   5,567,957  
Common Stock Dividends, Shares               90,625      
Shares Issued, Price Per Share (in Dollars per share)               $ 0.80      
Stock Issued During Period, Shares, New Issues               300,000      
Share-Based Payment Arrangement, Expense, after Tax (in Dollars)               $ 102,500      
Preferred Stock, Shares Authorized               100,000,000      
Dividends, Preferred Stock (in Dollars)               $ 995,455 $ 548,363    
Stock Issued During Period, Value, New Issues (in Dollars)           $ 1,655,500          
Stock Issued During Period, Value, Issued for Services (in Dollars)             $ 897,000        
Share-Based Payment Arrangement, Option [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars)               $ 0      
Series A Preferred Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Preferred Stock, Shares Authorized               500,000      
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01   $ 0.01  
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)               $ 25      
Preferred Stock, Dividend Rate, Percentage               12.00%      
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)               $ 25      
Preferred Stock, Shares Outstanding               0   0  
Series C Preferred Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Preferred Stock, Shares Authorized               3,000,000      
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01   $ 0.01  
Preferred Stock, Dividend Rate, Percentage               6.00%      
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)               $ 1.05      
Preferred Stock, Shares Outstanding               0   0  
Preferred Stock, Convertible, Conversion Price (in Dollars per share)               $ 0.25      
Series D Preferred Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Preferred Stock, Shares Authorized               10,000,000      
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01   $ 0.01  
Preferred Stock, Dividend Rate, Percentage               6.00%      
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)               $ 1.05      
Preferred Stock, Shares Outstanding               250,000   250,000  
Common Stock, Convertible, Conversion Price, Increase (in Dollars per share)               $ 0.25      
Dividends, Preferred Stock (in Dollars)               $ 7,855      
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)               $ 41,654      
Series E Preferred Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Stock Issued During Period, Shares, New Issues         10,000            
Preferred Stock, Shares Authorized               10,000      
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)         $ 0.01            
Preferred Stock, Convertible, Conversion Price (in Dollars per share)         $ 0.05            
Stock Issued During Period, Value, New Issues (in Dollars)         $ 1,000            
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)         $ 1,100            
Series F Preferred Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Preferred Stock, Shares Authorized               140,000     140,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01   $ 0.01 $ 0.01
Preferred Stock, Shares Outstanding               20,057   20,057  
Dividends, Preferred Stock (in Dollars)               $ 941,713      
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)               $ 2,497,786      
Preferred Stock, Value, Outstanding (in Dollars)                     $ 1,000
Series X Preferred Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Common Stock Dividends, Shares 24,555 25,013 41,057                
Shares Issued, Price Per Share (in Dollars per share) $ 0.80 $ 0.80 $ 0.80                
Preferred Stock, Shares Authorized               31,427      
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)               $ 0.01   $ 0.01  
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)               $ 25      
Preferred Stock, Shares Outstanding               31,427   24,227  
Dividends, Preferred Stock (in Dollars)               $ 45,886      
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)               $ 0      
Preferred Stock, Dividend Payment Terms               The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration.      
Share Price (in Dollars per share)       $ 0.80              
Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date       20.00%              
Preferred Stock, Voting Rights               Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.      
Series X Preferred Stock [Member] | Officers and Directors [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Stock Issued During Period, Shares, Issued for Services               7,200      
Stock Issued During Period, Value, Issued for Services (in Dollars)               $ 180,000      
Series X Preferred Stock [Member] | Director [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Stock Issued During Period, Value, Issued for Services (in Dollars)               $ 60,000      
Common Stock [Member]                      
Stockholders' Equity (Deficit) (Details) [Line Items]                      
Share Price (in Dollars per share)       $ 1              
v3.24.2.u1
Stockholders' Equity (Deficit) (Details) - Share-Based Payment Arrangement, Option, Exercise Price Range - $ / shares
6 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Share Based Payment Arrangement Option Exercise Price Range Abstract    
Range of exercise prices $ 1.5  
Number of options outstanding (in Shares) (in Shares) 13,667 100,934
Weighted average remaining contractual life (years) 5 years 9 months 14 days  
Weighted average exercise price of outstanding options $ 1.5 $ 10.01
Number of options exercisable (in Shares) (in Shares) 13,667  
Weighted average exercise price of exercisable options $ 1.5  
v3.24.2.u1
Stockholders' Equity (Deficit) (Details) - Share-Based Payment Arrangement, Option, Activity
6 Months Ended
Jun. 30, 2024
$ / shares
shares
Share Based Payment Arrangement Option Activity Abstract  
Outstanding, Number of Shares | shares 100,934
Outstanding, Weighted-Average Exercise Price | $ / shares $ 10.01
Options Vested and Exercisable, Number of Shares | shares 13,667
Options Vested and Exercisable, Weighted-Average Exercise Price | $ / shares $ 1.5
Granted, Number of Shares | shares 0
Granted, Weighted-Average Exercise Price | $ / shares $ 0
Cancelled/Expired, Number of Shares | shares (87,267)
Cancelled/Expired, Weighted-Average Exercise Price | $ / shares $ 11.38
Exercised, Number of Shares | shares 0
Exercised, Weighted-Average Exercise Price | $ / shares $ 0
Outstanding, Number of Shares | shares 13,667
Outstanding, Weighted-Average Exercise Price | $ / shares $ 1.5
v3.24.2.u1
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range - USD ($)
6 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]    
Range of exercise prices $ 30.64 $ 30.64
Number of warrants outstanding (in Dollars) $ 673,208  
Weighted average remaining contractual life (years) 2 years 2 months 1 day  
Weighted average exercise price of outstanding warrants $ 30.64 30.64
Number of warrants exercisable (in Shares) 673,208  
Weighted average exercise price of exercisable warrants $ 30.64 $ 30.64
Range of exercise price $2.50 [Member]    
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]    
Range of exercise prices $ 2.5  
Number of warrants outstanding (in Dollars) $ 874  
Weighted average remaining contractual life (years) 3 years 9 months 21 days  
Weighted average exercise price of outstanding warrants $ 2.5  
Number of warrants exercisable (in Shares) 874  
Weighted average exercise price of exercisable warrants $ 2.5  
Range of exercise price $25.00 [Member]    
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]    
Range of exercise prices $ 25  
Number of warrants outstanding (in Dollars) $ 366,784  
Weighted average remaining contractual life (years) 2 years 2 months 23 days  
Weighted average exercise price of outstanding warrants $ 25  
Number of warrants exercisable (in Shares) 366,784  
Weighted average exercise price of exercisable warrants $ 25  
Range of exercise price $37.50 [Member]    
Stockholders' Equity (Deficit) (Details) - Schedule Of Warrants Purchase Exercise Price Range [Line Items]    
Range of exercise prices $ 37.5  
Number of warrants outstanding (in Dollars) $ 305,550  
Weighted average remaining contractual life (years) 2 years 1 month 9 days  
Weighted average exercise price of outstanding warrants $ 37.5  
Number of warrants exercisable (in Shares) 305,550  
Weighted average exercise price of exercisable warrants $ 37.5  
v3.24.2.u1
Stockholders' Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights
6 Months Ended
Jun. 30, 2024
$ / shares
shares
Schedule Of Stockholders Equity Note Warrants Or Rights Abstract  
Outstanding, Number of Shares | shares 673,208
Outstanding, Weighted Average Exercise Price | $ / shares $ 30.64
Granted, Number of Shares | shares 0
Granted, Weighted Average Exercise Price | $ / shares $ 0
Exercised, Number of Shares | shares 0
Exercised, Weighted Average Exercise Price | $ / shares $ 0
Outstanding, Number of Shares | shares 673,208
Outstanding, Weighted Average Exercise Price | $ / shares $ 30.64
v3.24.2.u1
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]    
Derivative liabilities $ 152,945 $ 152,945
Fair Value, Inputs, Level 1 [Member]    
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]    
Derivative liabilities 0 0
Fair Value, Inputs, Level 2 [Member]    
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]    
Derivative liabilities 0 0
Fair Value, Inputs, Level 3 [Member]    
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]    
Derivative liabilities $ 152,945 $ 152,945
v3.24.2.u1
Commitments and Contingencies (Details) - USD ($)
6 Months Ended
Apr. 10, 2024
Apr. 02, 2024
Jan. 11, 2024
Dec. 21, 2023
Dec. 15, 2023
Nov. 14, 2023
Oct. 25, 2022
Oct. 22, 2022
Jun. 30, 2024
Oct. 14, 2021
Oct. 08, 2021
Sep. 28, 2021
Sep. 21, 2021
Jun. 08, 2021
May 04, 2021
Nov. 01, 2020
Commitments and Contingencies (Details) [Line Items]                                
Litigation Settlement, Fee Expense     $ 3,000       $ 3,000                  
Stock Issued During Period, Shares, New Issues (in Shares)                 300,000              
Lessee, Operating Lease, Term of Contract         114 months 2 years 6 months       96 months 108 months 94 months 90 months 8 years 7 years 8 years
Lessee, Operating Lease, Liability, to be Paid         $ 1,153,000 $ 244,000     $ 99,477 $ 767,000 $ 1,153,127 $ 1,079,000 $ 782,000 $ 620,000 $ 673,000 $ 511,000
Settled Litigation [Member]                                
Commitments and Contingencies (Details) [Line Items]                                
Litigation Settlement, Amount Awarded to Other Party $ 530,000                              
Settled Litigation [Member] | Restricted Stock [Member]                                
Commitments and Contingencies (Details) [Line Items]                                
Stock Issued During Period, Shares, New Issues (in Shares)             2,552                  
Judicial Ruling [Member]                                
Commitments and Contingencies (Details) [Line Items]                                
Litigation Settlement, Amount Awarded to Other Party   $ 425,351     $ 488,491 $ 348,764   $ 219,576                
Loss Contingency, Actions Taken by Plaintiff       A stipulation for Judgment was filed on December 21, 2023, in the amount of $415,266. The stipulated judgment includes $178,542 in unpaid back rent, $172,124 in resolution of mechanics’ liens, and $64,600 in attorneys’ fees.                        
CEO of The Good Clinic [Member] | Settled Litigation [Member] | Restricted Stock [Member]                                
Commitments and Contingencies (Details) [Line Items]                                
Stock Issued During Period, Shares, New Issues (in Shares)             19,622                  
v3.24.2.u1
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION $ 7,145,127  
SETTLEMENT AMOUNT 96,136 $ 121,136
Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 2,452,768  
Nordhaus Minneapolis, MN [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 511,000  
Nordhaus Minneapolis, MN [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 0  
Prominade Wayzetta, MN [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 407,000  
Prominade Wayzetta, MN [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 25,000  
Eagan Clinic Eagan, MN [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 767,000  
Eagan Clinic Eagan, MN [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 488,491  
Excelsior & Grand St. Louis Park, MN [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 673,000  
Excelsior & Grand St. Louis Park, MN [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 425,350  
The Grove St. Paul, MN [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 1,153,000  
The Grove St. Paul, MN [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 415,606  
Elevate Eden Prarie [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 620,000  
Elevate Eden Prarie [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 0  
Arbor Lakes Maple Grave, MN [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 1,153,127  
Arbor Lakes Maple Grave, MN [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 219,575  
LMC Welton Denver, CO [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 782,000  
LMC Welton Denver, CO [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT 530,000  
1776 Curtis Denver, CO [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
ORIGINAL OBLIGATION 1,079,000  
1776 Curtis Denver, CO [Member] | Settled Litigation [Member]    
Commitments and Contingencies (Details) - Schedule of Property Settlement Obligations [Line Items]    
SETTLEMENT AMOUNT $ 348,764  
v3.24.2.u1
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
3 Months Ended
Jul. 29, 2024
Jul. 19, 2024
Jul. 18, 2024
Sep. 30, 2024
Subsequent Events (Details) [Line Items]        
Selling and Marketing Expense $ 10,000      
Monthly compensation fee 11,250      
Annualy compensation fee $ 135,000      
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) 200,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award 200,000 shares of restricted common stock of which 100,000 is considered immediately earned, 50,000 are considered earned as of December 31, 2024, and the final 50,000 are considered earned as of June 30, 2024      
Share-Based Payment Arrangement, Expense       $ 75,000
Shares Issued, Price Per Share (in Dollars per share)       $ 0.25
Director [Member]        
Subsequent Events (Details) [Line Items]        
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) 300,000      
Restricted Stock [Member]        
Subsequent Events (Details) [Line Items]        
Share-Based Payment Arrangement, Expense       $ 50,000
Shares Issued, Price Per Share (in Dollars per share)       $ 0.25
Cavalry Fund Note [Member]        
Subsequent Events (Details) [Line Items]        
Proceeds from Issuance of Debt     $ 25,000  
Debt Instrument, Term     12 months  
Debt Instrument, Interest Rate, Stated Percentage     10.00%  
AJB Note [Member]        
Subsequent Events (Details) [Line Items]        
Proceeds from Issuance of Debt   $ 25,000    
Debt Instrument, Term   12 months    
Debt Instrument, Interest Rate, Stated Percentage   10.00%    
Mercer Street Capital [Member]        
Subsequent Events (Details) [Line Items]        
Proceeds from Issuance of Debt   $ 25,000    
Debt Instrument, Term   12 months    
Debt Instrument, Interest Rate, Stated Percentage   10.00%    
Three Director [Member]        
Subsequent Events (Details) [Line Items]        
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) 100,000      

Mitesco (PK) (USOTC:MITI)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Mitesco (PK) Charts.
Mitesco (PK) (USOTC:MITI)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Mitesco (PK) Charts.